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ABSTRACT OF THESIS

THE EFFECT OF PITUITARY PARS INTERMEDIA DYSFUNCTION ON
PROTEIN METABOLISM AND INSULIN SENSITIVITY IN AGED HORSES
Equine pituitary pars intermedia dysfunction (PPID) typically occurs in horses
older than 15 years of age and is characterized by hair coat abnormalities, muscle atrophy
and decreased insulin sensitivity. The first objective of this research was to compare the
rate of whole body protein metabolism and relative abundance of key factors in the
signaling pathways associated with muscle protein synthesis and protein breakdown in
response to feeding in Control and PPID horses. No differences (P > 0.05) were seen
between the PPID and Control groups in whole-body protein metabolism or post-prandial
activation of the muscle signaling pathways regulating skeletal muscle protein synthesis
and breakdown. The second objective of this research was to determine if aged horses
with PPID had reduced insulin sensitivity and alterations in the insulin-mediated
signaling pathways in the skeletal muscle when compared to non-PPID, aged Control
horses. Measures of insulin sensitivity and the activation of factors associated with
protein synthesis and breakdown were similar between the PPID and Control groups (P >
0.05). Overall, insulin sensitivity and protein metabolism are similar between the PPID
and Control groups. The studies suggest that abnormalities may exist as a function of
advanced age rather than PPID status directly.
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CHAPTER I.
The literature review
1.1 INTRODUCTION
The focus of this review is to examine the literature pertaining to the current
knowledge of pituitary pars intermedia dysfunction (PPID) in aged horses, specifically as
it relates to changes in insulin sensitivity and protein metabolism. A summary of the
prevalence, physiology, and clinical signs associated with PPID will be followed by a
brief overview of the disease as seen in other species. Next, diagnostic methods and
treatments for PPID will be discussed. This will be followed by a synopsis of insulin
resistance (IR) in the horse including the role of insulin especially as it relates to aged
horses, current techniques that are being used in the assessment and diagnosis of IR, and
other conditions that may cause IR will be given. Finally, protein metabolism in the horse
and other relevant species will be reviewed, including an overview of the factors that
regulate whole-body protein synthesis and breakdown, the signaling pathways that
regulate muscle protein synthesis and degradation, a brief overview of the methods used
to study whole-body and muscle protein metabolism, and the effects of old age on protein
metabolism.

1.2 PITUITARY PARS INTERMEDIA DYSFUNCTION
Pituitary pars intermedia dysfunction (PPID), commonly known as Cushing’s
disease, is estimated to affect 15% to 30% of horses older than 15 years of age (1, 2).
However, estimates of its prevalence vary greatly likely due to lack of a set of universally
accepted diagnostic criteria (3). In an Australian survey of aged horses older than 15
1

years of age, only 1.7% of owners reported having a horse with Equine Cushing’s
syndrome, but 22% of owners reported that their horse had a change in hair coat, a
common clinical sign of PPID (4). The onset of PPID usually occurs in horses 18 to 20
years old and very rarely occurs in horses younger than 10 years of age (5). Despite
initial reports, it does not appear that the disease has a greater prevalence based on breed
(6) or sex (7) of the horse.
1.2.1 Physiology of PPID

The equine pituitary gland is made up of four different regions: pars distalis, pars
intermedia, pars tuberalis and pars nervosa (Figure 1.1). PPID occurs when an adenoma,
hypertrophy, or hyperplasia is present on the pars intermedia of the horse’s pituitary
gland.
In both the pars distalis and the pars intermedia, pro-opiomelanocortin (POMC) is
produced by corticotropes and melanotropes, respectively. POMC is further processed to
yield adrenocorticotropic hormone (ACTH) and β-lipotropin in the pars distalis by
prohormone convertase 1 (PC1). PC1 is expressed in both corticotropes and
melanotropes, whereas prohormone convertase 2 (PC2) is only expressed in
melanotropes. PC2 further cleaves ACTH to α-melanocyte-stimulating hormone (αMSH) and corticotropin-like intermediate lobe peptide (CLIP) and cleaves β-lipotropin to
β-endorphin (β-END), lipotrophin and other small peptides, which are released into the
bloodstream (Figure 1.2) (8). In a healthy horse, nearly all ACTH is produced in the pars
distalis; however, in a horse affected by PPID, ACTH is also produced in the pars
intermedia. Therefore, horses with PPID have increased levels of anti-inflammatory
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hormones, ACTH and α-MSH. A study of hormonal changes in these horses found that
ACTH was elevated to a similar level to that of human Cushing’s disease; however, αMSH, β-MSH, CLIP and β-END were found to be disproportionately increased (9).
Dopamine is known to negatively regulate POMC production in the horse by
inhibiting prohormone convertase activity in the pars intermedia. In horses with PPID, an
adenoma on the pars intermedia causes dopamine production to decrease leading to an
increase in POMC-derived peptides. Specifically, a study of pars intermedia tissue found
that horses with PPID had 8-fold less dopamine concentration than the tissue from aged
matched controls (10). Additionally, another study found that horses with PPID had a 6fold reduction in dopaminergic nerve terminals (11). Prohoromone convertase is
inhibited by dopamine and in a study of mice lacking a dopamine receptor PC1 activity
increased 4-5 fold and PC2 activity increased 2-3 fold (12). Similar changes are believed
to occur in horses with PPID, since PPID affects dopamine receptors in the pars
intermedia (9). These changes cause ACTH to be produced at a faster rate than it can be
cleaved and thus net ACTH production occurs in the pars intermedia, as well as the pars
distalis.
In a study of horses injected with a dose of ACTH twice a day for four days,
ACTH increased plasma cortisol concentrations (13). Additionally, glucose
concentrations were higher in horses receiving ACTH and a transient increase in insulin
concentration was seen. Horses with PPID have been shown to have elevated ACTH and
α-MSH; however an increase in plasma cortisol has not been seen (14, 15). The
mechanism that would explain this phenomenon is currently unclear. Ultimately, the
physiological changes that occur as a result of PPID lead to a variety of clinical signs.
3

1.2.2 Clinical Signs

There are many clinical signs associated with PPID and horses can be highly
variable in their presentation of these clinical signs (Table 1.1). In the early stages of
PPID, it is possible to have very few or no clinical signs present. The classical sign of
PPID is hypertrichosis, characterized by a long, curly hair coat that fails to shed, as well,
delayed shedding, incomplete shedding, and lightening of the hair coat may be present.
Pathogenesis of this clinical sign is unknown although it has been hypothesized that it
may occur as a consequence of chronic elevations in MSH peptides due to their known
role on skin cells (14). Due in part to their long hair coat, horses with PPID have been
reported to have an increased incidence of hyperhidrosis or excessive sweating. However,
excessive sweating has been reported even in a cool environment or when the horse is
body clipped, suggesting that hyperhidrosis may be caused by other factors in addition to
the long hair coats (5).
Weight loss and muscle atrophy, primarily in the epaxial and gluteal musculature,
has also been reported to be associated with PPID (8). Studies of muscle atrophy in
horses with PPID revealed atrophy of type 2 fibers, sarcoplasmic lipid accumulation,
increased myofiber size variation, and increased proteolysis which is consistent with
increased glucocorticoid production as seen in other species (16, 17). Combined with
muscle loss, horses with PPID may also have abnormal distribution of fat along the crest
of the neck, over the tail head and behind the eyes. A proposed mechanism of this
occurrence is that hyperinsulinemia seen in many horses with PPID, may contribute to fat
deposition by inhibiting lipolysis (5).

4

Insulin resistance is also commonly reported in association with PPID; however,
it is unclear if it is directly associated with PPID. Two studies have been published
comparing insulin sensitivity in horses with PPID to younger healthy horses. In both of
these studies, the horses with PPID were found to be less insulin sensitive than their
younger counterparts (18, 19), when an intravenous glucose tolerance test and
euglycemic hyperinsulinemic clamp were used to assess insulin sensitivity. Interestingly,
a study compared aged (>15 years old) horses with confirmed PPID (positive
dexamethasone suppression test (DST), hirsutism, and at least one other clinical sign),
horses with unconfirmed PPID (positive DST, but no hirsutism) and healthy controls
(negative DST and no hirsutism) (20). The study found that horses with confirmed PPID
had higher basal levels of plasma glucose and insulin compared to both the unconfirmed
PPID and control group. It has been suggested that high serum insulin concentrations,
may be the cause of laminitis in horses (21, 22). In a study of 40 horses with laminitis,
70% were found to have PPID as defined by a plasma ACTH concentration greater than
35 pg/mL. Laminitis is the major clinical complication associated with PPID and is often
the reason for euthanasia in these horses (7).
Other clinical signs of PPID include, polyuria and polydipsia, increased
opportunistic infections, immunosuppression, behavior abnormalities and neurologic
disease (8). It is important to note that while all of the clinical signs discussed are
believed to be associated with PPID, the prevalence of very few of the clinical signs have
been compared with healthy aged horses. In a study of 165 Thoroughbreds looking at the
ACTH-immunoactive cells of the pars intermedia, 5 out of the 165 mares had an enlarged
pituitary gland consistent with PPID although none of the horses in this study exhibited
5

clinical signs (23). While many clinical signs have been reported to be associated with
PPID, the mechanistic cause of most of these signs and the interrelationships between
these symptoms remains unknown.
1.2.3 Cushing’s disease in other species
As previously mentioned, PPID was referred to as Equine Cushing’s disease
(ECD) or Equine Cushing’s syndrome (ECS) in most scientific literature up until the late
1990s and these terms are still seen in some of the recent literature, particularly in studies
published outside of the United States or in Veterinary Medicine journals. Additionally,
popular press articles, veterinarians, and other people in the equine community, generally
still refer to PPID as ECD.
The term Cushing’s syndrome is, by definition, the clinical consequence of
glucocorticoids acting in excess of physiological requirements. Cushing’s syndrome was
first described by Harvey Cushing in human patients. He described the clinical features of
hypercortisolism in people with tumors of the pars distalis (PD), which is the most
common way people are affected by Cushing’s syndrome (24). Shortly after Harvey
Cushing first described Cushing’s disease, Pallaske (25) found a similar disease in horses
that became known as Equine Cushing’s disease (cited by Messer IV and Johnson (26)).
However, upon further research, it was determined that Cushing’s disease in horses is not
associated with elevated plasma cortisol (14, 15, 27), which may warrant an alternate
name for the described syndrome.
In humans, Cushing’s disease (CD) is rare. The estimated annual incidences of
human CD are in the range of 1.2 to 2.4 new cases per 1,000,000 (28, 29). Other than
6

pituitary tumors, Cushing’s syndrome in humans can also be caused by ectopic syndrome
(ACTH producing tumors), adrenal adenomas, and carcinomas at 12%, 10%, and 8% of
cases, respectively (30). Women are more prone to CD than men and may be 3 to 8 times
more likely to have the disease (30). As well, Cushing’s disease can occur at any age, but
age of diagnosis peaks from 25 to 50 years (30). Clinical signs associated with the disease
are truncal obesity where fat is distribution is concentrated in the trunk of the body rather
than extremities, facial fullness, glucose intolerance, gonadal dysfunction, hirsutism,
hypertension and muscle weakness. Table 1.2 shows the frequency of clinical signs and
symptoms associated with human CD as seen in a study by Boscaro et al. (30).
CD also occurs in other species, such as dogs and very rarely in cats. CD in dogs
occurs more commonly with 1 to 2 cases per 1,000 dogs diagnosed annually. Although
diagnosis is much more prevalent, canine CD is very similar in its clinical presentation to
human CD. Dogs with CD show clinical signs such as abdominal obesity, weight gain,
fatigue, muscle atrophy and skin changes. It has been proposed that dogs would make a
good animal model for the human form of CD (31). A comparison of the clinical signs of
CD as seen in humans, dogs and horses is seen in Table 1.3. The table shows the
similarities between dogs and human, yet there are few similarities of dogs and humans
to horses.
1.2.4 Use of PPID horses as a model for Parkinson’s disease

It has been suggested that horses with PPID may serve as the best animal model
for Parkinson’s disease (PD) in humans due to the significant similarities between the
two diseases. PD is a leading cause of neurologic disability in the elderly human
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population, but research determining the early, initiating factors have been limited due to
lack of a suitable animal model. PPID and PD are similar in that that they are both
spontaneous neuroendocrine diseases that affect aged populations (32).
Additionally, data supports that they are both associated with loss of function
dopaminergic periventricular neurons. As previously mentioned, a study by Millington et
al. (10) determined that horses with PPID had eight-fold less dopamine and dopamine
metabolites in the tissue of the pars intermedia compared with age-matched controls.
Current PD research suggests that oxidative stress is responsible for inducing damage,
which may be the contributing factor in neuronal dysfunction and death. Similarly,
examination of the horse’s pituitary shows increased oxidative stress in the dopaminergic
neurons of the pars intermedia with age and more severely with PPID (11). The study
found that horses with PPID had 16 times more 3-nitrotyrosine, a marker of oxidative
stress, in the pituitary and hypothalamus and aged horses without PPID had 7 times more
3-nitrotyrosine than young horses.
Another similarity between PPID and PD is in the neuronal accumulation and
aggregation of α-synuclein in nerve terminal protein. α-synuclein is a natively unfolded,
soluble monometic protein that can improperly fold and aggregate in the nerve terminals
and leukocytes. The accumulation of improperly folded α-synuclein disrupts cellular
function and will eventually cause cell death (33). The accumulation and aggregation of
α-synuclein is known to contribute to PD. As well, horses with PPID have been shown to
have 1.7 times more α-synuclein in the pituitary compared with both healthy aged horses
and younger controls (33).
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Despite their apparent similarities, the diseases do differ in several important
aspects. First, in horses with PPID the adenoma occurs on the pars intermedia, but in
humans with PD the tumor occurs on the pars distalis. Due to this difference, clinical
signs of the two diseases are not the same. The second major difference is the lack of
Lewy body formation in the horse, which is a marker of PD (33).
Due to the limitations of the model, it is likely the horse model will be best
utilized in investigating the early, systemic events that lead to PD; however, its usage
may provide a unique perspective into PD (33).
1.2.5 Diagnosis of pituitary pars intermedia dysfunction

One of the most reliable indicators of PPID is the presence of hypertrichosis,
which can positively predict PPID status 90% of the time based on post-mortem
evaluation (34); however, hypertrichosis is not present in all horses with PPID,
particularly in early stage cases (5). For this reason, laboratory tests are often used to
diagnose and confirm PPID status. There are many diagnostic methods and this review
will focus on three: plasma ACTH concentration, plasma α-MSH concentration and
dexamethasone suppression test (DST). In addition, there are several other tests that have
been investigated, including thyroid releasing hormone stimulation test, domperidone
response test, serum insulin concentration, cortisol circadian rhythm loss, urinary
cortisol/creatinine ratio and use of magnetic resonance imaging; however, these methods
are not as well-established (8). Each of these tests can be beneficial to diagnosing PPID;
however, none are 100% accurate in detecting PPID. Ultimately, post-mortem evaluation
of the pituitary gland of the horse is the only way to accurately determine PPID status,
but in clinical practice this is not possible, and therefore, alternate diagnostic tests must
9

be performed. It is important to find a test that is highly correlated to the results of postmortem evaluation and that can be easily performed in a clinical setting.
It is known that the adenoma on the pituitary gland of the horse can increase
ACTH and α-MSH production. When the concentrations of these hormones are
measured, levels outside of the normal range may indicate PPID status. Plasma ACTH
and α-MSH concentrations are determined by taking a single blood sample collected in
an EDTA tube. PPID diagnosis is based on an ACTH concentration greater than 40-50
pg/mL (35) and α-MSH concentration greater than 35 pmol/L (36). During the fall
months, both of these tests can be greatly affected by seasonality, where a natural rise in
ACTH and α-MSH occurs in the later part of August to mid-September and declines by
October. α-MSH has the greatest seasonal effects as it increases over 3 times its normal
range in the fall months from August to October (8). Beech et al. (37) determined that it
might be necessary to have seasonal reference ranges of 90 pmol/L for the fall months in
order to accurately diagnose PPID using α-MSH concentration. Additionally, α-MSH is
not available as a commercial test, so this diagnostic method is not commonly used in
veterinary practice, although it has proven useful in research settings. ACTH is not as
seasonally affected as α-MSH (8); however, it can be elevated due to stress, exercise and
other biological factors (38).
The dexamethasone suppression test was once considered the goal standard in
PPID diagnosis. To perform this test, dexamethasone is administered intramuscularly at a
dose of 0.04 mg/kg and then a blood sample is taken 19-20 hours post dexamethasone
administration. Diagnosis for PPID is positive if dexamethasone does not suppress blood
cortisol levels below 1 μg/dL, 19-20 hours later. In healthy aged horses, administering
10

dexamethasone inhibits ACTH release from the pars distalis leading to the suppression of
cortisol, whereas horses affected by PPID have a decreased ability to suppress cortisol
since ACTH produced in the pars intermedia is not regulated by glucocorticoid feedback.
A study by Dybdal et al. (39) found that DST has nearly 100% sensitivity and 100%
specificity in diagnosing PPID at 19-20 hours post dexamethasone administration when
evaluated post-mortem. In this case, sensitivity refers to the test’s ability to correctly
identify a horse with PPID as having PPID and specificity refers to the test’s ability to
correctly identify a non-affected horse as negative for PPID. However, later studies
showed that this test might not be nearly as accurate as initially reported (40).
A later study compared the three diagnostic tests for specificity and sensitivity
(40). These tests were evaluated based on post-mortem evaluation of the ratio of the pars
intermedia to the total pituitary area. During this study, 105 clinically normal horses and
15 with the clinical signs of PPID were tested for PPID using all 3 diagnostic methods
and then evaluated post-mortem. Using the ratio pars intermedia area to total pituitary
area of greater than 0.3 as a positive diagnosis for PPID, sensitivity and specificity in
non-fall samples for the ACTH test was 71% and 81%, for α-MSH was 63% and 90%,
and for DST was 65% and 95%, respectively. While all three diagnostic tests were poor
at correctly identifying non-end stage cases of PPID, the best results (sensitivity=80%,
specificity=90%) were obtained when both DST and α-MSH were performed and a
positive result from either test was used to indicate PPID status. The results indicate that
it may be necessary to use more than one diagnostic test to more accurately diagnose
PPID.
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1.2.6 Treatments for PPID

Horses with PPID have additional considerations in both general geriatric
management as well as pharmaceutical treatment of the disease. For horses with PPID,
nutrition, parasite control and hoof care have even greater importance. Due to the
possibility of increased incidence of insulin resistance and laminitis (41), feeds with
highly soluble carbohydrates should be avoided. Currently, many companies have diets
formulated specifically for horses with insulin resistance, such as Purina’s WellSolve
L/S® and Intégri-T®. Proactive deworming strategies should be employed for horses with
PPID due to the increased risk of strongyle infections (36). Additionally, due to their long
hair coat, horses with PPID may need to be body clipped and provided with ample shade
during the summer months.
There are two drugs commonly used to treat PPID: pergolide mesylate and
cyproheptadine. Pergolide is currently the most commonly used drug due to its ability to
down regulate POMC derived peptide production by acting as a dopamine D2 receptor
agonist (8). The drug was originally used to treat Parkinson’s disease, but was voluntarily
withdrawn from the market in March 2007 (42), due to the 33% increase in vascular heart
disease seen in human Parkinson’s patients using pergolide, compared with those who
had never used the drug (43). The withdrawal of human pergolide created a problem for
veterinarians since there was not a commercially available product containing pergolide
that was approved for use in horses. Since increased heart lesions have not been reported
in horses, the Food and Drug Administration (FDA) issued a limited exemption, allowing
pergolide to be compounded in bulk for veterinary use (42).
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Reports have demonstrated pergolide’s ability to significantly lower plasma
ACTH concentrations in horses with PPID (7, 44, 45). In 40-60% of the horses, ACTH
was lowered to within normal range (9-35 pg/mL)(44, 45). Horses treated with pergolide
had ACTH concentrations significantly lower than those horses treated with
cyproheptadine (7, 44). Further Donaldson et al. (44) found that 85% (17/20) of owners
with horses on pergolide reported an improvement in the clinical signs associated with
PPID compared with only 28% (2/7) of owners of the horses treated with cyproheptadine.
In September 2011, PRASCEND® Tablets were approved for use in horses with
PPID (NADA 141-331). According to Hagyard pharmacy, a major veterinary pharmacy
in Lexington, KY, the approximate cost of PRASCEND® Tablets is $1.95/per tablet with
most horses requiring 1 tablet (1 mg of pergolide mesylate per tablet) per day. Due to the
high cost, it is essential that a horse be correctly diagnosed with PPID.
Cyproheptadine is a mixed-action drug, which acts as a serotonin antagonist and
has antihistamine and antimuscarinic effects or the ability to block muscarinic receptors
(8). Blocking muscarinic recptors helps to increase the level of dopamineragic activity.
The use of cyproheptadine has limited success when compared to pergolide (7, 44);
however, it may be beneficial for some equines. It has been suggested that may be useful
in combination with pergolide when maximal doses of pergolide alone are unsuccessful
in resolving the clinical signs (8). As well, cyproheptadine’s effectiveness may be
underestimated because Perkins et al. (45) found that there was no difference in the
amount that plasma ACTH decreased between horses treated with pergolide and horses
treated with cyproheptadine. Additionally, the study found that 81% of horses (26/32)
treated with cyproheptadine and 90% (9/10) treated with pergolide showed improvement
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of at least one clinical sign. Currently, cyproheptadine is not approved by the FDA for
use in horses, despite being used in accepted practice. According to Hagyard pharmacy, a
major veterinary pharmacy in Lexington, KY, the cost of Cyproheptadine 4mg Tablets is
$104.71 for 1,000 (4mg) tablets. With most horses requiring 0.5 mg/kg BW per day (45),
a 500 kg horse will require 250 mg per day, at a cost of about $6.50 per day.

1.3 INSULIN SENSITIVITY IN THE HORSE

PPID is believed to be associated with decreased insulin sensitivity; however, as
previously discussed, this relationship has not been well described in the scientific
literature. Despite the lack of conclusive research, popular press articles and feed
companies marketing low starch feeds continue to associate PPID with insulin resistance.
The next section of this literature review will discuss the physiological roles of insulin,
the concept of insulin resistance, methods used to measure insulin sensitivity in the horse,
insulin resistance in aged horses and conditions other than PPID that may cause a
decrease in insulin sensitivity in horses.
1.3.1 Physiological roles of insulin

Insulin is a dipeptide, containing A and B chains, that are linked by disulphide
bridges and contains 51 amino acids. Insulin is synthesized as its precursor, proinsulin, by
the β-cells of the pancreatic islets of Langerhans. Proinsulin is synthesized in the
ribosomes of the rough endoplasmic reticulum (RER) from mRNA as pre-proinsulin.
When the signal peptide is removed from pre-proinsulin, proinsulin is formed which is
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transferred from the RER to the Golgi apparatus. Then, enzymes acting outside the Golgi
apparatus convert proinsulin to insulin and C-peptide (46, 47).
Insulin secretion from the islet cells into the portal vein is pulsatile and increases
post-feeding (48). In response to a glucose stimulus, insulin secretion is biphasic meaning
an initial rapid phase of insulin secretion occurs followed by a less intense, but more
sustained insulin release (49). Increased levels of glucose induce the first phase of
glucose-mediated insulin secretion by the release of insulin from the secretory granules of
the β-cells. The process occurs when glucose entering the β-cell is sensed by glucokinase,
which phosphorylates glucose to glucose-6-phosphate, generating ATP. Then potassiumATP dependent channels close, resulting in membrane depolarization and activation of
calcium channels. When calcium channels open, intracellular calcium concentrations
increase leading to a pulsatile secretion of insulin (50). Insulin secretion can also be
stimulated by other factors such as stimulation of the vagus nerve when food is seen,
smelled or acutely ingested (51). Peptide hormones such as glucagon- like peptide-1
(GLP-1) enhance insulin secretion (52) while somatostatin (53) and leptin (54) inhibit
insulin secretion. Additionally, amino acids, particularly arginine (55), ornithine (56) and
leucine (57), have been shown to stimulate insulin secretion.
Upon secretion, insulin interacts with its target cells by binding to specific sites on
the plasma membrane called receptor sites (58). Insulin acts on cells in the skeletal
muscle, liver and fat. Insulin binds to the α subunit of the receptor site causing a
conformational change, which then allows ATP to bind the β subunit of the receptor site.
The main insulin receptor in the cell involves tyrosine kinase. This interaction is rapid,
reversible and triggers a series of internal events that results in the movement of glucose15

transporter proteins (GLUT4) to the cell surface for glucose uptake. GLUT4 appears the
major transporter that mediates the insulin response (59). Ultimately, the role of insulin is
to maintain normal blood glucose levels by facilitating cellular glucose uptake. The major
sites of insulin mediated glucose uptake include the skeletal muscle and adipose tissues.
Insulin secretion facilitates glucose uptake by the cells, promotes glycolysis,
glycogenesis, protein synthesis and ion uptake and inhibits gluconeogenesis,
glucogenolysis, lipolysis, ketogensis and proteolysis (Figure 1.3) (60).
In the horse, insulin secretion has a distinct circadian rhythm with maximum
secretion at 1200h. (61, 62). The pattern of this rhythm does not appear to be affected by
PPID status or hay versus concentrate diet as seen in two independent studies (61, 62).
Additionally, horses show a significant post-feeding rise in plasma insulin concentration
when fed concentrate, but little increase in insulin concentration when hay is fed (63).
This is due to increased levels of glucose post-feeding, inducing glucose-mediated insulin
secretion (47) and dietary amino acids such as arginine and leucine which are known to
increase insulin secretion (64). Insulin release is decreased during stress and exercise, due
to the increase in circulating catecholamines, which inhibit insulin secretion (65). In the
horse, this inhibition occurs at about 50% of VO2max which allows the horse to increase
gluconeogenesis to maintain blood glucose during exercise (65).
1.3.2 Insulin Resistance

Insulin resistance (IR) is defined as a condition where normal concentrations of
insulin produce a subnormal physiologic response (66). It occurs when tissues are not as
responsive to the actions of insulin, usually due to defects in post receptor insulin
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signaling. When the tissues no longer elicit the proper response to insulin, the body may
compensate by increasing insulin secretion. This is known as compensatory
hyperinsulinaemia and occurs when pancreatic β-cell secretion increases in order to
maintain normal blood glucose. In humans, the state is maintained until pancreatic
secretory defects occur and the inability to compensate for decreased insulin sensitivity
results in increased blood glucose concentrations and type 2 diabetes. In humans, IR is a
characteristic of type 2 diabetes and is different from the reduction in insulin production
as seen in type 1 diabetes (67). However, diabetes mellitus in the horse is rare, but it may
be underdiagnosed in aged horses (68). Horses commonly compensate for decreased
insulin sensitivity in two ways. First, a horse may compensate by increasing pancreatic βcell release and insulin secretion in order to maintain insulin-mediated glucose uptake.
Alternatively, a horse may increase glucose-mediated glucose uptake (glucose uptake not
related to insulin, which occurs primarily in the fasted state) in order to decrease the
concentration of plasma and extracellular glucose (69).
In the horse, insulin resistance may occur due to a reduction in the density of
insulin receptors on the cell surface, malfunction of insulin receptors, defects in internal
signaling pathways or interference with the translocation or function of GLUT4 proteins
(70). To distinguish between the different causes of IR, two terms were adopted. The
first, insulin sensitivity, describes reduced insulin-mediated glucose transport into the
cell. The second, insulin ineffectiveness, describes a failure of insulin-facilitated
intracellular glucose utilization (21, 69). These two types of IR may exist separately or
together depending on the specific case of IR.
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1.3.3 Conditions associated with insulin resistance in the horse

As previously discussed, insulin resistance (IR) may be associated with PPID (18,
19); however, there are many other conditions that are also associated with IR. It has
been suggested that IR is a factor causing many equine diseases, such as laminitis (71),
hyperlipidemia (72) and osteochondritis dessicans (OCD) (73). This review will
specifically discuss the role of IR in laminitis, as well as other factors that affect IR such
as body condition, activity, diet and age.
1.3.3.1 Insulin resistance and laminitis
IR was first associated with laminitis in the 1980’s when two studies found that
ponies with a history of laminitis were more likely to be insulin resistant that horses with
no history of laminitis (71, 72). Additionally, more recent studies had similar findings
using basal proxies, reciprocal of the square root of insulin (RISQI) and modified insulin
to glucose ratio (MIRG) (74, 75). A further discussion of these proxies can be found in
Section 1.3.4.2. Analysis of these proxies indicated that the ponies predisposed to
laminitis had lower insulin sensitivity (RISQI) and higher insulin response (MIRG),
indicating a compensatory exaggeration of pancreatic β-cell secretion (75). In healthy
horses, a study demonstrated that laminitis can be induced due to prolonged
hyperinsulinemia within 48 hours (76).
Although, it is well defined that decreased insulin sensitivity and laminitis are
associated, the cause of this relationship is unknown. Studies have shown that laminitic
episodes may be able to be predicted using insulin, leptin and measures of generalized
and localized obesity (77). It was initially suggested that insulin-mediated
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vasoconstriction may be responsible for causing laminitis (72). More recent hypotheses
include compromised glucose transport into insulin-dependent cells (21, 78), since
glucose deprivation has been shown to result in the separation of hoof connective tissue
(79). While there are many hypotheses of the known relationship between insulin
resistance and laminitis, none of them have been proven to be the cause of all laminitis
cases; therefore, it is likely that this is complex relationship that will require further
research in order to gain a better understanding.
1.3.3.2 Factors affecting insulin resistance in the horse

IR is affected by many different factors, but it may be particularly affected by age
(80) body condition (81), activity level (82), and diet (83).
The relationship between insulin resistance and age is well known; however, the
cause of this relationship is unclear (84). In human studies, insulin sensitivity was found
to decrease with age, beginning at 30 years of age and continuing throughout the
remainder of a person’s lifetime (85). However, a separate study found that when
adjusted for increased body weight with age this relationship was no longer significant
(86).
A study found that older horses (27±0.2 yrs) needed nearly 200% and 150%
more insulin to respond to an oral glucose tolerance test than young (6.8±0.4 yrs) and
middle-aged (15.2±0.4 yrs) mares, respectively (87). Additionally, tumor necrosis factorα (TNF-α) has been suggested to lead the development of insulin resistance and a study
of mice found the TNF-α increased with age. This relationship was investigated in the
horse in a study by Vick et al. (88). The study used the EHC procedure to assess insulin
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sensitivity in sixty mares and found that insulin sensitivity was negatively correlated with
body condition score, age, and TNF-α. The results of this study support previous
associations that high concentrations of circulating insulin and reduced insulin sensitivity
occurs in mares with high BCS and these effects may be exacerbated by aging (88).
The study was hardly the first to associate IR and obesity in horses. Several
studies have reported decreased insulin sensitivity in obese horses when compared to
their lean counter parts (81, 83). The decrease in insulin sensitivity seen in obese horses
seems to improve with weight loss due to both calorie restriction and exercise (81).
Additionally, fat distribution, such as neck crest adiposity, has been shown to be
negatively correlated with insulin sensitivity in horses and ponies (89). The relationship
between insulin resistance and obesity may be due to increased inflammation that occurs
with obesity. Administration of lipopolysaccharide (LPS) induces an inflammatory
response with increased concentration of inflammatory cytokines, particularly TNFα.
Administration of LPS was found to induce insulin resistance within 24 hours in horses
(90).
In human studies, exercise has been shown to improve IR even when weight loss
does not occur (91). Similarly, a study of both lean and obese mares found that exercise
improved insulin sensitivity without a change in body weight after 7 days of round-pen
exercise (82). Stewart-Hunt et al. (92) suggested that these findings are due to the effect
of training on insulin action. They found that GLUT-4 content and glycogen synthase
activity increased with short-term training and these enhancements were still evident after
5 days of inactivity. Alternatively, another study found that exercise training alone
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without dietary restriction did not improve insulin sensitivity in overweight or obese
horses (93).
It is also important to understand the relationship between diet and IR. A study by
Hoffman et al. (83) showed that healthy horses adapted to sweet feeds that are high in
non-structural carbohydrates, such as starch and sugars, had decreased insulin sensitivity.
Additionally, the study results suggested that the effect of non-structural carbohydrates
may be magnified in horses with preexisting IR. A second study found that weanlings
adapted to a sugar and starch diet had decreased insulin sensitivity when compared to
weanlings on a fat and fiber diet; however, this decrease in insulin sensitivity appeared to
be compensated for with increased β-cell secretion of insulin (94).
Overall, there are many factors that can affect insulin sensitivity in the horse and
many of these factors are interrelated. It is important to understand these risk factors in
order to assess a horse’s risk for insulin resistance.
1.3.4 Methods used to measure insulin sensitivity

There are many methods used to measure insulin sensitivity, each with its own
advantages and disadvantages. Depending on the specific situation, it may be necessary
to use one or a combination of these methods in order to quantify insulin sensitivity in the
horse. While there are many methods that can be employed, this review will focus on
five methods including, basal hyperglycemia and hyperinsulinemia, proxies and surrogate
testing, glucose tolerance test, minimal model of glucose-insulin dynamics and the
euglycemic-hyperinsulinemic clamp (EHC) technique.
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1.3.4.1 Basal hyperglycemia and hyperinsulinemia

Measurement of fasting plasma glucose and insulin concentrations is a simple
screening test that involves a single blood sample. The technique may be useful in
obtaining some information about insulin sensitivity with minimal effort on the part of
the person testing. Measuring plasma glucose is not extremely effective due to its
inability to differentiate between inadequate secretion of insulin by pancreatic β-cells or a
decrease in insulin sensitivity of tissues (95). Conversely, basal hyperinsulinemia was
once considered a certain sign of IR; however, upon further research new methods were
developed which gave a better indication of the insulin sensitivity of the horse. Basal
hyperinsulinemia only occurs when insulin insensitivity of the tissues is overcompensated
for by increased insulin secretion; however, decreased insulin sensitivity caused by
decreased secretion of insulin will not be detected (95). Therefore, basal
hyperinsulinemia may be useful to detect some cases of IR, but not others. When
measuring plasma glucose and insulin concentrations, the cutoff value for hyperglycemia
and hyperinsulinemia has not been well defined. The cutoff values of 5.5 mmol/L and 36
µIU/mL have been suggested for hyperglycaemia and hyperinsulinaemia in adult horses,
respectively (20).
1.3.4.2 Proxies and surrogate tests

Several simple tests have been developed to determine IR in humans. These
screening tests are based on equations that use fasting plasma glucose and insulin
concentration. In human medicine, there are many screening tests used, including
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HOMA-IS, QUICKI, RISQI and MIRG. Table 1.4 shows the full names and equations
used to calculate these proxies.
While commonly used in humans, the use of these proxies has only been recently
investigated in the horse. A study by Treiber et al. (96) compared the use of different
proxies to the minimal model of glucose and insulin dynamics determined using a
frequently sampled intravenous glucose tolerance test, a much more intensive procedure
known to accurately measure insulin sensitivity. The study found that RISQI (r=0.774)
was the best predictor of insulin sensitivity and MIRG (r= 0.754) was the most accurate
predictor of β-cell responsiveness. The combined use of these proxies allows for the
assessment of insulin response and compensatory insulin secretion. The authors proposed
that the use of these may be useful in research on large populations or in clinical
situations requiring convenient and cost-effective evaluations of insulin resistance where
a dynamic test cannot be performed and nonspecific indicators, such as basal
hyperinsulinemia, do not characterize cause of insulin resistance (96).
1.3.4.3 Glucose tolerance testing

The glucose tolerance test measures the plasma glucose response to an oral or IV
administration of a specified dose of glucose using the time integral or area under the
curve. This test was originally developed to classify carbohydrate tolerance in humans.
However, because plasma glucose and insulin responses during this test may reflect the
ability of pancreatic β-cells to secrete insulin and tissues sensitivity to insulin, the test has
also been used to evaluate IR (97).
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Recently, the oral sugar test was developed to test horses in the field. The test
works by orally administering corn syrup using a syringe at a dose of 15 mL per 100 kg
BW. Then, a single blood sample is taken 60-90 minutes later. An insulin concentration
greater than 60 µU/mL at this time is indicative of insulin resistance in the horse (98).
The glucose tolerance test may be useful in horses since it is does not require as much
labor and time as some of the other diagnostic methods for IR. The major limitation of
the test is that glucose intolerance does not necessarily coexist with IR. The test cannot
distinguish between factors, such as insulin secretion or insulin sensitivity, which may
cause failure of glucose homeostasis (99). Despite the limitations of this method, it has
been considered evidence of IR in several studies of horses including horses with PPID
(18), fasted ponies (100), mature obese ponies (101) and laminitic ponies (72).
1.3.4.4 Minimal model analysis of the frequently sampled intravenous glucose tolerance
test

The minimal model of glucose-insulin dynamics is a dynamic test of insulin
resistance, which divides glucose disposal into two parts, glucose and insulin-mediated
disposal. The model describes the glucose time curve as 2 differential equations. The first
represents glucose-mediated glucose disposal by use of as single rate constant and the
second represents insulin mediated glucose disposal by use of a rate constant and insulin
sensitivity (95).
An application of the minimal model is in the modified frequent sampling i.v.
glucose tolerance test (FSIGT). To perform the technique, a bolus of glucose is
administered intravenously. Then 20 minutes after the glucose bolus, an insulin bolus is
administered at a dose, which would accelerate glucose disposal, but not promote
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hypoglycemia. The technique lasts 3-4 hours and blood samples are taken frequently (13 minutes between samples) particularly in the first 30 minutes and then the time between
samples increases to approximately 30 minutes in the last 1-2 hours of the procedure
(83).
Plasma insulin and glucose concentrations during sampling are determined and
used to calculate four output measures. Glucose effectiveness (Sg), insulin sensitivity
(Si), acute insulin response to glucose (AIRg) and the disposition index (DI) must be
calculated using computer software. A diagram of the minimal model used to interpret
the modified FSIGT is shown in Figure 1.4. To define these terms, glucose effectiveness
(Sg) refers to the capacity of glucose to mediate its own disposal independent of a change
in plasma insulin and insulin sensitivity (Si) refers to the capacity of insulin to promote
its own disposal. Acute insulin response to glucose (AIRg) quantifies the endogenous
insulin secretion in response to the glucose dose. Disposition index (DI) describes β-cell
responsiveness and accounts for the influence of endogenous insulin secretion (AIRg)
and Si (83).
The frequent sampling makes this a labor-intensive procedure requiring many
trained personnel to properly perform the technique. Additionally, concerns have been
raised about the calculation of glucose-mediated disposal using a single-rate constant
which may not always adequately describe the glucose component of the model (102).
1.3.4.5 Euglycemic hyperinsulinemic clamp technique

The euglycemic hyperinsulinemic clamp (EHC) technique was introduced in
human medicine by DeFronzo et al. (103) and gained initial acceptance as the best
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method to quantify IR. Later, this technique was applied for use in the horse (82). To
perform the technique, the horse must be outfitted with two catheters, one to infuse
glucose and insulin and the second to obtain blood samples. The method replicates a state
of hyperinsulinemia by infusing insulin at a constant rate that is based on the horse’s
body weight. During the insulin infusion, frequent blood samples are taken and analyzed
for glucose concentration using an automated analyzer. Then the rate of glucose infusion
is subsequently adjusted in order to maintain euglycemia. When the rate of glucose
infusion reaches plateau the rate of glucose infusion is assumed to equal the rate of
glucose disposal (104).
The EHC technique was found to be more repeatable than the minimal model
analysis of the FSIGT for determining insulin sensitivity in the horse (105). This may
make it more desirable for studies where the same horse is studied multiple times.
Additionally, the EHC technique is advantageous for situations where the horse needs to
be in an insulin-stimulated state at the end of the procedure as in the case of a muscle
biopsy. While the EHC is a well-accepted technique, the method does not come without
some disadvantages. It is labor intensive, as many samples need to be collected in order
to maintain stable glucose concentrations. Additionally, the technique determines the
sensitivity of tissues to insulin; however, it does not account for the sensitivity of β-cells
to glucose. It has also been argued that the conditions of the EHC are non-physiologic,
since the measured glucose disposal rate corresponds to an abnormally high insulin level
(102). However, this can be avoided by using lower rates of insulin infusion that create a
more physiologic state as seen in several studies (82, 88).
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1.4 PROTEIN METABOLISM IN THE HORSE

Protein metabolism refers to the sum of all biochemical processes required for
protein synthesis and protein breakdown. This review will cover protein synthesis as it is
regulated through the mTOR pathway, suppression of the mTOR pathway by myostatin
and protein breakdown as it is regulated through the ubiquitin-proteasome pathways and
factors that interact with this pathways of protein breakdown including the FoxO family
and NF-κB. This will be followed by a review of isotope infusion methodology to study
protein metabolism and the effect of aging on whole body protein metabolism.
1.4.1 Protein synthesis and the mTOR pathway

The process of protein synthesis occurs when the nucleotides in mRNA are
decoded into amino acids that are linked via peptide bonds in order to form a new
protein. The process of protein synthesis can be divided into three stages: initiation,
elongation, and termination. A number of the components involved in initiation and
elongation stages of translation are controlled by the mechanistic, formally known as
mammalian, target of rapamycin (mTOR) pathway (106). The mTOR signaling pathway
was initially discovered in 1991 in yeast cells (107) and has been extensively studied in
the skeletal muscle of humans (108, 109), rodents (110, 111), piglets (112-114) and to a
lesser extent in the horse (115, 116). The mTOR pathway has been the subject of many
recent reviews (106, 117, 118). Briefly, mTOR is phosphorylated and activated by a
number of upstream pathways, which are activated by factors such as insulin, amino
acids and exercise. Upon activation, mTOR affects a series of downstream regulators
leading to an increase in protein synthesis. A simplified schematic of this pathway can be
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seen in Figure 1.5. The effects of mTOR on protein synthesis will be further discussed in
this review, including upstream pathway activators and downstream effectors. The ability
of myostatin to suppress protein synthesis will be reviewed and this will be followed by a
summary of what is currently known about mTOR signaling in the skeletal muscle of
horses.
1.4.1.1 Activation of mTOR

Insulin is a major activator of the mTOR pathway through Akt, which is also
known as protein kinase B (PKB). In this interaction, a subunit activated by insulin
phosphorylates Akt at the Ser473 and Thr308 phosphorylation sites, activating Akt (119).
Activation of Akt leads to activation of mTOR by inhibiting negative regulators of
mTOR known as 40 kDa protein rich Akt substrate (PRAS40) and tuberous sclerosis 2
(TSC2) (120, 121). Akt is also responsible for phosphorylation of transcription factors,
forkheadbox protein O1 (FoxO1) and forkheadbox protein O3 (FoxO3) (111, 122). These
factors are involved in regulation of protein breakdown and activate the expression of
genes regulating apoptosis. A further discussion of this regulation can be found in Section
1.3.2. Additionally, activation of Akt results in the movement of glucose transporter 4
(GLUT4) to the cell membrane resulting in the transport of glucose in the cell (123).
Movement of glucose into the cells does not directly influence mTOR signaling
(124); however, cellular energy is needed to drive mTOR signaling. ATP is produced by
glucose as a product of glycolysis. When levels of ATP in the cell are high, AMP
activated protein kinase (AMPK) activity is inhibited (125). Similarly, when levels of
ATP are low and levels of AMP are high, AMPK becomes active. Ultimately, through a
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series of phosphorylations AMPK inhibits mTOR by phosphorylating regulatoryassociated protein of mTOR (RAPTOR) (110, 126). Therefore, any physiological state,
which effects glucose metabolism, will in turn affect mTOR (127) .
Intracellular amino acids stimulate mTOR signaling through a system of amino
acid transporters that move the amino acids from the blood to the muscle. Particularly,
arginine and leucine have been identified as key amino acids that stimulate mTOR (128,
129). Studies have demonstrated the ability of leucine enriched mixture to decrease
phosphorylation of eEF2, which promotes elongation and stimulated muscle protein
fractional synthesis rates (130). It is unclear how amino acids stimulate mTOR activation;
however, mitogen-activated protein 4 kinase kinase kinase (MAP4K3), PI3K catalytic
subunit type 3 (VPS34) and Rag GTPases have been identified as potential mediators.
When MAP4K3 is stimulated by amino acids it is believed to activate S6K1 independent
of mTOR (131). VPS34 may be the primary modulator of mTOR signaling in response to
amino acids and it has been suggested that VPS34 is required for leucine stimulation of
S6K1 (132). The Rag GTPases become activated in the presence of amino acids and
interact with RAPTOR resulting in mTOR relocation onto the surface of endosomes and
lysosomes. This movement may enable allow mTOR to interact with Ras homolog
enriched in brain (Rheb) leading to mTOR activation (133). Ultimately, amino acids
stimulate protein synthesis specifically at the points of translation and elongation.
Exercise has been shown to increase protein turnover leading to an increase in
muscle fiber size; however, during aerobic exercise mTOR signaling is suppressed.
Several mechanisms have been proposed for the decrease in mTOR signaling during
aerobic exercise. One way that exercise suppresses mTOR signaling is by increasing the
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expression of regulated in development and DNA damage response 1 (REDD1), a
hypoxia induced gene. REDD1 activates TSC1/2 complex, leading to a reduction in
mTOR signaling (134). Other proposed mechanisms include suppression of mTOR by
AMPK (135) and suppression of mTOR due to a decrease in eEF2 phosphorylation (136).
Some exercise increases skeletal muscle contractile activity increasing the mechanical
stimulation of muscle fibers. Mechanical stimulation increases the activity of mTOR,
thus increasing protein synthesis and leading to an enlargement in muscle fibers (137).
Following short-term resistance exercise in rodents, an immediate increase in mTOR
signaling factors was seen (138), particularly in the downstream effectors leading to
protein synthesis. mTOR signaling is suppressed during exercise and then increased to
during the recovery period leading to muscle hypertrophy (138).
1.4.1.2 Downstream regulators of mTOR

Following the activation of mTOR, a series of cell signaling events lead to the
initiation of mRNA translation into protein. When mTOR is activated, 70kDa S6 kinase 1
(S6K1) and eukaryotic initiation factor (eIF) 4E-binding protein 1 (4EBP1) become
phosphorylated through RAPTOR (139).
Once activated, S6K1 phosphorylates several downstream proteins required for
RNA processing and mRNA translation initiation, including ribosomal protein S6 (rps6)
and eIF4B. rps6 is an important factor known to aid in the determination of cell growth
by controlling cell size and cell division (140). rps6 knockout mouse embryo fibroblasts
have been shown to have an accelerated cell division due to a shortened G1 phase (141).
S6K1 and rps6 activation was initially thought to be important to up regulate translational
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capacity by enhancing the translation of components required for protein synthesis;
however this theory has been disproven (142, 143). When phosphorylated, eIF4B is
required for ribosomal recruitment to mRNA through a ribosomal subunit pre-initiation
complex (144). Ultimately, S6K1 plays an important role in the regulation of cell growth,
cell cycle progression, and cell proliferation (145).
mTOR activation leads to the phosphorylation of 4EBP1, a regulator of the eIF4F
complex that is required in the initiation of cap-dependent mRNA translation (146).
When 4EBP1 is phosphorylated, it separates from eIF4E. This allows eIF4E to associate
with eIF4G, which leads to the formation of the initiation complex, eIF4F. Once this
complex is formed, initiation is followed by elongation and thus protein synthesis occurs
(147).
1.4.1.3 mTOR signaling in the skeletal muscle of horses.

The molecular signaling pathway that regulates protein synthesis has been
extensively studied in cell culture (107) , rodents (110, 111) , neonatal piglets (112-114)
and humans (108, 109) ; however, only few recent studies have looked at mTOR
signaling in the horse (115, 116). A study of mTOR in the horse demonstrated that the
anabolic stimulus of meal consumption increased mTOR signaling, which agrees with the
results of previous studies in other species (115). When the post-feeding response of
yearlings, 2 year olds and mature horses were compared, the greatest increase in mTOR
signaling factors occurred in the yearling horses (116). Another study investigated the
effect of repeated muscle biopsies over a 5 days period on mTOR signaling. It was
determined that mTOR signaling, specifically phosphorylation of S6K1, rpS6 and
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4EBP1, is increased with repeated muscle biopsies. However, phosphorylation of these
mTOR signaling factors was not altered by repeated biopsies when an oral antiinflammatory was administered (148). Additionally, mTOR signaling does not appear to
be affected by muscle biopsy depth in horses (149).
1.4.1.4 Myostatin

Myostatin, also known as growth and differentiation factor 8 is a member of the
transforming growth factor-β superfamily and a negative regulator of skeletal muscle
mass. Disrupted myostatin gene expression is associated with increased skeletal muscle
mass resulting from muscle fiber hyperplasia and hypertrophy (150). Studies have
demonstrated that recombinant myostatin protein inhibits muscle cell proliferation and
protein synthesis in vitro (151). Additionally, dexamethasone administration, which has
been shown to decrease skeletal muscle mass (152), leads to increased myostatin
expression in rats (153). Further, when dexamethasone was administered to mice with the
myostatin gene deleted, skeletal muscle atrophy did not occur (154).
Myostatin leads to muscle atrophy through phosphorylation of Smad2 and Smad3,
which block muscle differentiation. Smad 2 and Smad3 activation are both required in
order for myostatin to inhibit protein synthesis (155). It has been demonstrated that
myostatin inhibits the activation of Akt, TORC1 and p70 leading to decreased protein
synthesis and muscle loss (155). Interestingly, although inactivation of Akt usually leads
to upregulation of MuRF1 and atrogin-1, the study found MuRF1 and atrogin-1
expression were downregulated by myostatin (155). Therefore, the authors hypothesized
that myostatin can block the induction of muscle’s differentiation program (155).
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1.4.2 Protein breakdown

The degradation of protein is important for the control of growth and in normal
metabolism. Protein breakdown allows for protein turnover and provides quality control
by selectively eliminating abnormally folded proteins. However, when the rate of protein
breakdown exceeds the rate of protein synthesis, muscle atrophy occurs (156). Muscle
atrophy is defined as a decrease in muscle mass including a decrease in size and number
of skeletal muscle fibers. The pathways regulating protein synthesis and breakdown are
highly interrelated. When protein synthesis occurs, it inhibits factors associated with
muscle atrophy and when atrophy occurs protein synthesis pathways are inhibited (157).
A simplified schematic of the proposed relationship between protein synthesis and
breakdown can be seen in Figure 1.6. Muscle protein breakdown is regulated
predominantly through the ubiquitin-proteasome pathway, as well as through the
lysosomal and calpain pathways (158). These pathways associated with protein
breakdown may be altered by various physiologic states such as aging (111, 159), insulin
resistance (157), and during postprandial and post-absorptive states (160). This review
will specifically cover the ubiquitin-proteasome pathways and factors that interact with
this pathways of protein breakdown, including the FoxO family and NF-κB.
1.4.2.1 Ubiquitin-proteasome pathway

The ubiquitin proteasome pathway is responsible for the degradation of most of
the skeletal muscle proteins (158). Ubiquitin is a small highly conserved regulatory
protein that, when added to a protein substrate, regulates signaling processes associated
with muscle atrophy. Three unique enzymatic components are required in this signaling
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process, including E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme, and
E3 ubiquitin-ligating enzyme (161). Currently, several hundred distinct E3s have been
identified and it is likely that each of these ubiquitin-ligating enzymes regulates
ubiquitination of a specific set of substrates (162). Therefore, the regulation of
ubiquitination can be part of a coordinated signaling pathway, analogous to
phosphorylation. Rates of protein degradation increase through the ubiquitin proteasome
pathways protein synthesis is blocked (163) and the amount of polyubiquitin conjugation
compared to total protein increase (164). Additionally, mRNA levels of genes that encode
ubiquitin-conjugating enzymes that are part of the ubiquitin pathway were found to
increase during atrophy (165).
1.4.2.2 MuRF1 and atrogin-1

The genes for two E3 ubiquitin ligases have been shown to increase in expression
in multiple models of skeletal muscle atrophy. These genes are known as muscle-RING
(really interesting new gene)-finger protein 1 (MuRF1) and muscle atrophy F-box
(MAFbx; also known as atrogin-1) (166). Consistent increases in the gene expression of
these two factors have been observed in models of skeletal muscle atrophy including
diabetes, cancer, and adrenal failure (167). MuRF1 encodes a protein that contains three
domains required for ubiquitin-ligase activity (168) and formation of heterodimers
between MuRF1 and MuRF2 (169). MuRF1 has been demonstrated to be in the nucleus
and may have a role in both regulation of myofibril assembly and muscle gene expression
(170). Atrogin-1 contains three domains including an F-box domain. An experiment in
mice revealed that when MuRF1 and atrogin-1 knockout mice were compared to their
littermates, all mice appeared phenotypically normal. However, when subject to
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physiologic conditions that would usually cause muscle atrophy, significantly less muscle
mass was lost in the knockout animals (166). The requirement of MuRF1 and atrogin-1
for skeletal muscle atrophy makes them potential targets for drug discoveries since they
are required for muscle atrophy, are expressed specifically in muscle cells, and do not
seem to be required for normal muscle growth and function (171).
1.4.2.3 FoxO family

The FoxO family is an important factor in the ubiquitin proteasome pathway of
protein breakdown that when activated leads to protein breakdown through increasing the
expression of atrogin-1 (172). Members of the forkhead box containing protein, O subfamily or FoxO family of transcription factors have been shown to play a variety of roles
in the cellular processes including longevity, metabolism and reproduction and regulation
of gene transcription (173). There are 3 primary members of the FoxO family: FoxO1,
FoxO3a and FoxO4. FoxO1 has been suggested to have a crucial role in vascular
formation (174). Both FoxO3a and FoxO4 null mice were viable and did not appear
phenotypically different from their littermates. However, female FoxO3a null mice were
infertile and had abnormal ovarian follicular development (174). Interesting, the FoxO3a
and FoxO1a genotype has been found to be strongly associated with longevity in humans
(175, 176). It is believed that the expression of the FoxO genes may help explain the
increased longevity seen in females (176).
Akt regulates the FoxO family through phosphoinositide-3-kinase (PI3K)
signaling. Thus, when Akt/PI3K is phosphorylated, FoxO is subsequently
phosphorylated and inactivated leading to decreased expression of atrogin-1 and
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ultimately a decrease in muscle atrophy (172). However, a study showed that FoxO3
could also be regulated in the absence of phosphorylated Akt through interaction with
IKKβ, a major catalytic subunit of IκB kinase complex (IKK). When this interaction
occurs, IKK phosphoryates FoxO3a, inhibiting it, and causes proteoloysis of FoxO3a via
the ubiquitination-dependent proteasome pathway. Downregulation of FoxO3a by IKK
can induce cell proliferation and tumorigenesis (177). Ultimately, the FoxO family of
transcription factors play an important role in upregulating factors associated with muscle
atrophy.
1.4.2.4 NF-κB
NF-κB is stimulated by inflammatory cytokines, particularly TNF-α, and leads to
increased expression of MuRF-1 (178, 179). In cells of the immune and inflammatory
systems, NF-κB was demonstrated to be an integration site for pro-inflammatory signals
and a regulator of inflammatory target genes (180). NF-κB activation increases the
production of cytokines and begins a positive feedback loop (178). Activation and
phosphorylation of NF-κB is controlled by phosphorylation of IKK (181). When the NFκB is activated, significant atrophy is induced due to upregulation of MuRF1, but not
atrogin-1 (179). However, without the presence of MuRF-1, activation of NF-κB did not
induce significant atrophy. Thus, it appears transcriptional activation of MuRF1 by NFκB is a necessary step in NF-κB induced atrophy and a linear signaling pathway had been
proposed between IKK, NF-κB, and MuRF1 (Figure 1.6). Alternatively, atrogin-1 is
stimulated by p38, a mitogen-activated protein kinase (MAPK), not NF-κB. A study
determined that TNFα stimulates atrogin-1 expression and atrogin-1 could not be
upregulated when p38 was blocked (182). p38 MAPK has been identified as a potential
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regulator of muscle catabolism and activity of p38 is increased in aging (183) and type II
diabetes (184). A study of endotoxin induced laminitis in horses found that
phosphorylation and thus activation of p38 peaked at 12 h of LPS infusion (185).
1.4.3 Introduction to whole body protein metabolism
The regulation of protein synthesis and breakdown is important to overall
metabolic and physiological homeostasis. The overall sum of protein synthesis and
breakdown can be measured and expressed as whole-body protein metabolism. Wholebody protein metabolism is affected by factors such as diet (186), age and exercise (187) .
These changes can be measured using isotope infusion techniques to measure rates of
whole-body protein synthesis and breakdown and muscle protein synthesis. This section
of the literature review will focus specifically on the isotope infusion methodology and
the effect of aging on whole body protein metabolism.
1.4.3.1 Isotope methodology

Whole body protein metabolism can be studied by infusing a stable amino acid
isotope, such as labeled leucine, glycine and phenylalanine. In studies of the horse, [113

C]phenylalanine has been used for isotope infusion (188, 189). An estimation of whole-

body protein synthesis is based on the principle that phenylalanine flux is equal to the
rate phenylalanine enters and exits the free amino acid pool and is calculated from the
dilution of labeled to unlabeled phenylalanine in the plasma. By measuring phenylalanine
flux and rates of phenylalanine oxidation to carbon dioxide (CO2) during isotope
infusion, rates of whole body synthesis and breakdown can be measured using a
stochastic approach (Figure 1.7) (190)
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The measurement of whole body protein synthesis is based on the ability to
calculate the amount of labeled phenylalanine isotope to unlabeled phenylalanine in the
plasma free amino acid pool. Urschel et al. (188) used the formulas established in human
studies (191) and applied these equations for use in the horse. Entering the pool, dietary
intake (I) refers to the estimated amount of phenylalanine coming from the diet. For the
horse, I was estimated as the dietary phenylalanine multiplied by 0.5 in order to account
for prececal phenylalanine digestibility and the dietary phenylalanine that is extracted
during the first-pass splanchnic metabolism (188). Also entering the pool, the release of
phenylalanine from protein breakdown (B) is measured by finding the difference between
phenylalanine flux (Q) and I.
Leaving the pool, phenylalanine oxidation to CO2 (E), known as oxidative
disposal, is measured by collecting breath samples. Also leaving the pool, phenylalanine
used in protein synthesis (Z) is measured by subtracting phenylalanine oxidation (E) from
flux (Q). Conversion to other metabolites (M) is assumed to be negligible as long as
tyrosine intake is equal between all treatment groups and in excess of estimated
requirements. The sum of these two parts (Z+M) is known as non-oxidative disposal.
Therefore, phenylalanine flux (Q) is assumed to equal the rate phenylalanine enters (I+B)
and exits (E+Z+M) the free amino acid pool.
1.4.3.2 Effect of aging on whole body protein synthesis

Studies of the effect of age on protein metabolism in humans have provided
largely mixed results. Some studies have shown that whole body protein metabolism
decreases with age (192), while others have shown no difference (187). Discrepancies
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between human studies may be due to differences in body composition and activity that
usually occur with increased age.
Short et al. (187) found that the rates of whole body muscle protein synthesis
declined with age. Although there was a reduction in the amount of fat-free mass that
occurred with age, when the rates of whole body protein synthesis were adjusted for fat
free mass, a negative correlation was still found between age and whole body protein
turnover. Additionally, the study suggested that some of the negative effects of aging on
whole body protein synthesis could be reversed with the addition of an exercise regimen.
Conversely, a study by Chevalier et al. (192), found that aging did not alter whole-body
insulin sensitivity and protein anabolic responses. The authors hypothesized that this was
due to similar muscle mass index and level of physical activity between the elderly and
young group. The study suggests that increased muscle atrophy that occurs with age may
be the result of increased adiposity and inactivity rather than from chronological age.
Ultimately, the relationship between aging and whole body protein metabolism is
complex and may be influenced by a number of factors including diet, body composition
and activity level.
1.4.3.3 Effect of aging on protein digestibility

Studies in humans have found that protein availability may decrease with age
(193). In human studies of young men, a slowly digested dietary protein (casein) lead to
greater protein gain than a quickly digested protein (whey); however, a subsequent study
showed that elderly males may benefit from a quickly digested protein compared with a
slowly digested protein in order to limit protein loss (193, 194). In horses, there is some
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evidence to support that protein digestion may decrease with advanced age. In an early
study, apparent crude protein digestion was reduced in aged horses (~25 yrs) when
compared with younger horses (~2 yrs) (195); however, in later studies of aged horses,
protein digestion was within the normal range of apparent protein digestion reported for
younger horses (196). Despite some evidence that protein requirements are different in
aged horses when compared to younger horses, the current edition of the NRC does not
make separate requirements due to inadequate support in the literature.
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1.5 TABLES:

Table 1.1: Reported prevalence of clinical signs of PPID in horses and ponies.
Clinical Sign

McFarlane

McGowan

Donaldson

Schott et

Couëtil

Hillyer

et al. (11)

et al. (61)

et al. (44)

al. (7)

et al.

et al. (27)

Total

(35)
Hirsutism

Laminitis

Hyperhidrosis

58%

100%

59%

83%

95%

94%

82%

(7/12)

(20/20)

(16/27)

(64/77)

(21/22)

(16/17)

(144/175)

-

80%

74%

52%

59%

82%

63%

(16/20)

(20/27)

(40/77)

(13/22)

(14/17)

(103/163)

30%

26%

33%

14%

59%

31%

(6/20)

(7/27)

(25/77)

(3/22)

(10/17)

(51/163)

-

Weight

42%

65%

15%

47%

50%

88%

48%

Loss/Muscle

(5/12)

(13/20)

(4/27)

(36/77)

(11/22)

(15/17)

(84/175)

33%

29%

9%

12%

27%

wasting
Abnormal fat

17%

distribution

(2/12)

Behavioral

8%

changes
PU/PD

Secondary
infections
a

50%
a

(10/20)

a

a

(2/17)

a

(9/27)

(22/77)

(2/22)

95%

19%

-

41%

82%

49%

(1/12)

(19/20)

(5/27)

(9/22)

(14/17)

(48/98)

0%

55%

7%

34%

32%

76%

34%

(0/12)

(11/20)

(2/27)

(26/77)

(7/22)

(13/17)

(59/175)

-

35%

30%

-

36%

48%

36%

(7/20)

(8/27)

(8/22)

(8/17)

(31/86)

= reports describing only suborbital fat distribution.

It is important to note that the prevalence of many of these clinical signs may be
overestimated due to more advanced cases of PPID selected due to the available
diagnostic methods.
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(47/175)

Table 1.2: Signs and symptoms of human Cushing’s syndrome 1 .
Sign/symptom

Frequency (%)

Truncal obesity

96

Facial fullness

82

Diabetes or glucose tolerance

80

Gonadal dysfunction

74

Hirsutism, acne

72

Hypertension

68

Muscle weakness

64

Skin atrophy and bruising

62

Mood disorders

58

Osteoporosis

38

Oedema

18

Polydipsia, polyuria

10

Fungal infections

6

The group consisted of 302 patients, 239 females and 63 males, with an average age of
38.4 years (SD : 13.5; range 8-75)
1

Adapted from Boscaro et al. (30)
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Table 1.3: Characteristics of human, canine and equine Cushing’s disease 1.

Clinical Sign

Human

Canine

Equine

Fatigue

+

+

+/-

Weight Gain

+

+

-

Truncal obesity

+

+

-

Muscle Atrophy

+

+

+

Osteoporosis

+

-

-

Hypertension

+

+

-

Polyuria/polydipsia

-

+

+

Thinning of skin

+

+

-

Easy bruising

+

-

-

Hirsutism

+

-

+

Alopecia

+/-

+

-

Hypercortisolism

+

+

-

+= present; -= not present
1

Adapted from de Bruin et al. (31)
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Table 1.4: Proxies adapted for basal glucose (mg/dL) and insulin (mU/L)
concentrations 1.
Proxy

Full name

Equation

HOMA-IS

Homeostasis model assessment- insulin
sensitivity

22.5/ (G X I)

QUICKI

Quantitative insulin sensitivity check index

(log[G X I])-1

RISQI

Reciprocal of the square root of insulin

I-0.5

MIRG

Modified insulin-to-glucose ratio

(800 - 0.30 x [I-50]2)/(G30)

G= glucose (mg/dL); I= insulin (mU/L) (
1

Adapted from Treiber et al. (96)
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1.6 FIGURES:

Figure 1.1: Schematic drawing showing the four lobes of the pituitary gland. The
pars intermedia is the region affected when a horse has PPID.
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Figure 1.2: Schematic drawing illustrating the production of hormones in the
pituitary gland of the horse. Both the corticotropes of the pars distalis and the
melanotropes of the pars intermedia produce POMC. In the pars distalis, PC1 converts
POMC to ACTH and β-lipotropin. In the pars intermedia, PC1 functions similarly, but
PC2 is also present to further cleave ACTH to α-MSH and CLIP and cleave β-LPH to βEND. In a horse affected by PPID, PC1 activity increases 4-5 fold and PC2 activity
increases 2-3 fold. These changes cause ACTH to be produced at a faster rate than it can
be cleaved and thus there is a net production of ACTH in the pars intermedia. (Adapted
from Dybdal et al. (39))
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Figure 1.3: Schematic drawing of the effects of insulin secretion on the body. Insulin
secretion increases glucose uptake, glycolysis, glycogen synthesis, protein synthesis and
ion uptake. When insulin is secreated, gluconeogenesis, glucogenolysis, lipolysis,
ketogensis and proteolysis decrease.
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Figure 1.4: Schematic represents the output measures of the minimal model used to
interpret the FSGTT. Sg represents glucose effectiveness (glucose-mediated glucose
disposal) and X represents insulin action (insulin-mediated glucose disposal). AIRg
represents the acute insulin response to glucose in the first 10 minutes after glucose
infusion. Insulin sensitivity (Si) is calculated as p3/p2 where p3 is the contribution of
plasma insulin to the remote compartment and p2 is the fractional rate of insulin clearance
from the remote compartment (Adapted from (99, 197))
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Figure 1.5: Schematic drawing of the mTOR pathway. Briefly, insulin stimulates the
phosphorylation and activation of Akt, which leads to activation of mTOR by inhibiting
negative regulators of mTOR known as PRAS40 and TSC2. mTOR activates S6Ks and
inhibits 4E-BPs leading to protein synthesis.
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Figure 1.6: Schematic drawing of the relationship between protein synthesis and
breakdown. The mTOR signaling pathway pathways is responsible for some of the
signaling associated with muscle atrophy. Akt inhibits the transcriptional upregulation of
Atrogin-1 and MURF1 via inhibition of the FoxO family of transcriptional factors.
Multiple factors can induce muscle atrophy including TNF-α and IL-1. Briefly, TNF-α
activates NF-κB, which leads to the activation of MuRF1. A second ligase atrogin-1 is
upregulated by MAPK p38 (Adapted from Glass (162)).
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Figure 1.7: Schematic drawing of whole body phenylalanine kinetics. Entering the
pool dietary intake (I) is measured phenylalanine in the feed and release of phenylalanine
from protein degradation (B) is measured by difference of phenylalanine flux and I.
Leaving the pool phenylalanine oxidation to CO2 (E) is measured by collecting breath
samples and phenylalanine use in protein synthesis (Z) is measured by subtracting
phenylalanine oxidation from flux. Conversion to other metabolites (M) is assumed to be
negligible assuming Tyr intake is equal in all treatment groups. Therefore, phenylalanine
flux equals the rate phenylalanine enters (I+B) and exits (E+Z+M) the free amino acid
pool. Flux is calculated from the dilution of the isotope by unlabeled phenylalanine in the
plasma.
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Chapter II
Rationale and Objectives

2.1 SCOPE OF THESIS

The overall objectives of the presented research are to examine the effects of
PPID on protein metabolism and insulin sensitivity. The horses used in these studies were
aged horses older than 20 years of age and consisted of horses with PPID and agematched, non-PPID controls. Stable isotope infusion was used to measure whole-body
protein metabolism and euglycemic hyperinsulinemic clamp (EHC) procedures were
used to measure insulin sensitivity. Additionally, muscle biopsies were collected in both
studies to examine the effects of PPID on the mTOR signaling pathway of protein
synthesis and markers in the protein degradation pathways.

2.2 RATIONALE

Estimates of the prevalence of PPID vary greatly, with high estimates suggesting
15 to 30% of aged horses are affected by PPID (8). While PPID may affect a large
number of horses, few studies have been conducted in order to understand the clinical
signs associated with this multi-faceted condition.
The effect of PPID on whole body muscle protein synthesis has not been looked
at in the current literature. Studies of horses with PPID have found that horses with PPID
have increased proteolysis, atrophied type 2 muscle fibers, sarcoplasmic lipid
accumulation and increased variation in myofiber size compared to age matched controls
(16, 17). It is possible that the muscle atrophy associated with these horses may be a
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result of decreased whole body protein synthesis due to decreased protein synthesis and
increased protein breakdown. Therefore, it is also important to look at some of these
factors associated with protein synthesis and breakdown in order to better characterize
muscle changes associated with PPID.
Further, the relationship between PPID and insulin sensitivity has not been well
characterized. Two studies found horses with PPID have decreased insulin sensitivity
compared to younger cohorts (18, 19); however, the difference in insulin sensitivity
between horses with PPID and age matched controls has not been studied. Understanding
the relationship between insulin sensitivity and PPID will be essential to better
management of horses with PPID.
Beyond just looking at insulin sensitivity in the horse, it is well known that insulin
affects a variety of metabolic functions in the body. One example of this is insulin
stimulating muscle protein synthesis through the mTOR pathway. Since horses with
PPID are believed to have muscle atrophy, specifically in the form of decreased type 2
fibers (17); it was important to understand the relationship between insulin response and
muscle protein synthesis. For this reason, muscle biopsies were taken both before and
after the euglycemic hyperinsulinemic clamp procedure and analyzed for factors
associated protein synthesis and degradation in order to better characterize the effects of
insulin on a muscle level.
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2.3 SPECIFIC HYPOTHESES AND OBJECTIVES
2.3.1 Hypothesis 1.
Hypothesis 1a: Horses with PPID will have lower rates of whole body protein
synthesis when compared to aged, non-PPID horses. Hypothesis 1b: Horses with PPID
will have decreased gluteal muscle mTOR signaling, following feeding, compared to
aged, non-PPID horses. Hypothesis 1c: Horses with PPID will have an increase in
protein degradation factors, following feeding, when compared with aged, non-PPID
horses.
The objective of the first study entitled, “Pituitary pars intermedia dysfunction
does not alter whole-body and muscle protein metabolism in aged horses”, was to
determine the effect of PPID on whole body protein synthesis and the pathways of
muscle protein synthesis and degradation when compared to aged, non-PPID controls. In
order to achieve this objective, whole body protein synthesis was assessed using isotope
infusion techniques (Hypothesis 1a). Additionally, a gluteal muscle biopsy was
performed 90 minutes post feeding on the day prior to the isotope infusion procedures.
The muscle samples were prepared and analyzed for factors associated with mTOR
signaling (Hypothesis 1b) and protein degradation (Hypothesis 1c) using Western
blotting.

2.3.2 Hypothesis 2.
Hypothesis 2a: Horses with PPID will have decreased insulin sensitivity when
compared to aged, non-PPID horses. Hypothesis 2b: Horses with PPID will have
decreased mTOR signaling, in response to insulin administration, when compared to
aged, non-PPID horses. Hypothesis 2c: Horses with PPID will have increased protein
54

degradation factors, in response to insulin administration, when compared to aged, nonPPID horses.
The objective of the second study entitled, “Pituitary pars intermedia dysfunction
does not affect insulin sensitivity in aged horses”, was to determine if horses with PPID
had reduced insulin sensitivity compared to age-matched, non-PPID controls. In order to
achieve this objective, insulin sensitivity was assessed using a euglycemichyperinsulinemic clamp procedure and calculation of two proxies, RISQI and MIRG
(Hypothesis 2a). Additionally, gluteal muscle biopsies were performed on the day prior
and immediately after the EHC procedure. The muscle samples were prepared and
analyzed for factors associated with mTOR signaling (Hypothesis 2b) and protein
degradation (Hypothesis 2c) using Western blotting.
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Chapter III
Pituitary pars intermedia dysfunction does not alter whole-body and muscle protein
metabolism in old horses.
3.1 INTRODUCTION
Pituitary pars intermedia dysfunction (PPID; also known as equine Cushing’s
disease) is believed to affect 15-30% of aged horses (1, 2). The disease results from the
loss of dopaminergic inhibition of the pituitary pars intermedia leading to increased
synthesis of proopiomelanocortin-derived peptides, α-melanocyte-stimulating hormone,
β-endorphin-related peptides, corticotropin-like intermediate lobe peptide and
adrenocorticotrophin (ACTH) (9). Clinical signs of PPID include hypertrichosis (198),
laminitis (41) , increased secondary infections (36), decreased insulin sensitivity (19), and
muscle atrophy (17).
In human studies, muscle atrophy has been associated with decreased whole-body
protein synthesis (199). In human patients with Cushing’s disease, whole-body protein
metabolism was altered due to increased protein breakdown, presumably due to changes
in body composition and glucocorticoid excess associated with Cushing’s disease (200).
In horses with PPID, basal cortisol levels are generally within the normal references
range (14, 15); however, it has been hypothesized that the cortisol circadian rhythm in
horses with PPID may be abolished leading to increased cumulative cortisol over a 24hour period (39). Therefore, it is unclear if similar alterations in whole-body protein
metabolism will be seen in horses with PPID compared to control horses. Isotope
infusion techniques to measure whole-body protein metabolism have been used
extensively in humans studies (187) and they have recently been validated for use in the
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horse (188). Studies in the horse have looked at the effects of old age on whole-body
protein synthesis; however, no differences were seen in whole-body protein metabolism
between the healthy aged (~ 25 yrs) and mature (~11 yrs) horses (201). Even though age
had no effect on whole-body protein metabolism, it may be possible that differences in
protein metabolism exist within an aged population, such as horses with PPID, where a
loss of muscle mass has been previously described (17).
Muscle atrophy occurs when the rate of protein degradation exceeds the rate of
protein synthesis. PPID is associated with muscle loss due to atrophy of type 2A and 2B
muscle fibers and loss of type 2B myofibers (17). The overall increase in glucocorticoids
proposed in horses with PPID (39) may lead to decreased protein synthesis and increased
protein breakdown at the muscle level. Horses with PPID do have increased expression of
a factor, m-calpain, which is part of the non-lysosomal calcium protease-dependent
system associated with protein breakdown (16). The results from the previous study
suggest that calpains may be associated with muscle atrophy that occurs in horses with
PPID; however, whether the pathways of protein synthesis or other pathways of protein
breakdown are involved still requires elucidation.
Protein synthesis is regulated through the mechanistic (formally mammalian)
target of rapamycin (mTOR) signaling pathway (106) and previous studies of the horse
have looked specifically at the factors, protein kinase B (Akt), eukaryotic initiation factor
4E-binding protein 1 (4E-BP1), and riboprotein S6 (rpS6), which when phosphorylated
lead to an increase in translation initiation and subsequently protein synthesis (202). Akt
activation also plays a role in protein degradation as it has been shown to phosphorylate
and inactivate nuclear transcription factors Forkhead box O (FoxO) (203). When FoxO is
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activated, it increases the expression key genes expressed during proteosomal protein
degradation, atrogin-1 and muscle RING finger 1 (MuRF1) (203). Muscle atrophy in the
horse may also be influenced by decreased protein synthesis due to upregulation of
negative regulators of protein synthesis, AMP-activated protein kinase (AMPK) (204)
and myostatin (155).
The objective of this study was to compare whole-body protein metabolism in
horses with PPID compared to age-matched, non-PPID controls. Further, the study aimed
to characterize differences between PPID and age-matched, non-PPID horses in the
activation of signaling pathways associated with muscle protein synthesis and breakdown
in response to feeding.

3.2 MATERIALS AND METHODS

3.2.1 Animals, housing, diets.

All procedures were approved by the University of Kentucky Institutional Animal
Care and Use Committee (2009- 0562). Twelve horses consisting of six horses with PPID
and six age-matched, non-PPID controls (CON) were obtained from the Department of
Veterinary Science’s Maine Chance Farm at University of Kentucky. Horses in the two
groups were of comparable age (PPID: 25.0±2.5 yrs; mean±SD; CON: 25.7±2.0 yrs) and
weight (PPID: 542±35 kg; CON: 500±50 kg). Additionally, both groups were comprised
of 4 mares and 2 geldings and all horses were of moderate body condition score (PPID:
5.5±0.5 CON: 5.0±0.7; [scale 1-9] (205)).
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Since the horses used in this study could not be evaluated post-mortem to assess
the presence of pituitary lesions, two diagnostic methods were used to determine PPID
status with the greatest possible accuracy (40). Horses were confirmed as PPID based on
resting ACTH greater than 50 pg/mL and serum cortisol greater than 1 μg/dL 19-20 hours
after dexamethasone administration. Horses classified as PPID based on these methods
had many of the clinical signs consistent with PPID, such as hirsutism and hair coat
abnormalities, hyperhydrosis, muscle atrophy, and a history of laminitis. In April 2012,
blood samples were collected in EDTA tubes (Vacutainer; Becton-Dickinson, Franklin
Lakes NJ) and analyzed for ACTH concentration (PPID: 103.6±73.7 pg/mL; CON:
23.3±8.2 pg/mL) using a hormone assay performed by an external laboratory (Animal
Health Diagnostic Center; Cornell University, Ithaca, NY). In May 2012, dexamethasone
suppression tests were performed according to previously described procedures (39)
where blood samples were collected into glass evacuated tubes containing no additive
(Vacutainer; Becton-Dickinson, Franklin Lakes NJ) before and 19-20 hours post
intramuscular administration of dexamethasone (DexaJect; Butler Schein Animal Health,
Dublin OH ) at 0.04 mg/kg. Serum cortisol was then analyzed using a hormone assay by
an external laboratory (Animal Health Diagnostic Center; Cornell University, Ithaca,
NY).
Horses were adapted to diets and housing for at least 2 weeks prior to the isotope
infusion procedures. All horses were housed in a single paddock with free access to
mixed grass hay (mean ± SD, as fed; 10.1± 0.1% crude protein, 33.0± 0.6% acid
detergent fiber, 50.9± 0.6% neutral detergent fiber, 2.7± 0.4% fat, and 6.5± 0.4% ash),
water, and salt blocks. Twice daily at 0700 and 1500, horses were fed a commercial
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concentrate designed for senior horses (mean ± SD, as fed; 14.1± 0.1% crude protein,
22.5± 0.7% acid detergent fiber, 37.2± 1.3% neutral detergent fiber, 6.2± 0.2% fat, and
7.4± 0.2% ash) (Purina® Equine Senior® Horse Feed, Purina Mills LLC, Gray Summit,
MO) individually in stalls (12g/kg BW/day, split between two meals), with the exception
of study days where the feeding procedure was modified as described below. Analysis of
the commercial concentrate and hay were performed by an external laboratory (Dairy
One Forage Laboratory; Ithaca NY).
3.2.2 Study procedures.

On the morning prior to the isotope infusion procedures, horses were weighed
and blood was collected immediately before (t=0) and 90 minutes after their 0700 meal to
measure postprandial changes in plasma glucose, insulin and amino acid concentrations.
According to previous research, horses reach peak amino acid concentration 90 to 180
minutes following a meal (206).
The following morning, a catheter (14 gauge × 14.0 cm, Abbocath; Abbott
Laboratories, North Chicago IL) was inserted into each jugular vein: one for isotope
infusion and a second for blood collection. In order to determine total CO2 production,
each horse received a 2 h primed (7.1 μmol/kg BW), constant (6.0 μmol/kg BW/h)
infusion of a [13C]sodium bicarbonate solution using a cordless IV pump attached to a
surcingle (J-1097 VetPro Infusion Pump, Jorgensen Laboratories Inc., Loveland, CO)
attachd to a surcingle worn by the horse. The sodium bicarbonate solution was prepared
by dissolving [13C]sodium bicarbonate (Isotec, Miamisburg, OH) in 0.9% sterile saline,
which was then transferred into a sterile ethylene vinyl acetate bag (Baxter Healthcare,
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Deerfield IL). Breath samples were taken at -30, -60, 0, 30, 60, 75, 90, 105 and 120
minutes of sodium bicarbonate infusion. Breath samples were obtained using a modified
Equine Aeromask® (Trudell Medical International, London ON, Canada) with a reversed
one-way valve to allow air to be trapped in gas impermeable bags (Wagner Analysen
Technik Vertriebs GmbH, Bremen, Germany). To collect breath samples, horses wore
the mask for one minute prior to sample collection to allow the air to equilibrate inside
the mask. Then the bag was attached to the one-way valve and was removed and capped
once it became full. During sodium bicarbonate infusion, baseline blood samples for
phenylalanine enrichment were taken at 90 and 120 minutes into the infusion.
At the end of the two hours, sodium bicarbonate infusion was stopped and a
second isotope infusion began immediately. Each horse received a 4-hour primed (10.2
μmol/kgBW), constant (7.2 μmol/kgBW/h) infusion of L-[1-13C] phenylalanine (Isotec,
Miamisburg, OH) in order to measure whole-body phenylalanine kinetics (207). The 1.5
prime to constant ratio was based on the findings of a previous study in horses (188). The
preparation and administration of the infusion solution and the breath sampling protocols
were as described above for the [13C]sodium bicarbonate infusion. Blood and breath
samples were taken and feed was given every 30 minutes after the start of isotope
infusion.
On the day of the isotope infusion procedures, horses received 1/48 of their
daily concentrate allocation every 30 minutes, beginning at least 90 minutes prior to the
start of the [13C]sodium bicarbonate infusion. To minimize changes in plasma
phenylalanine concentration as a result of the isotope infusion, the meals given prior to
the start of [1-13C]phenylalanine isotope infusion were top dressed with 0.6 mg/kg (3.6
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μmol/kg BW) of L-phenylalanine powder (L-phenylalanine, Sigma-Aldrich, St. Louis
MO).
3.2.3 Muscle biopsy.

Immediately prior to the biopsy, horses were lightly sedated with xylazine
hydrochloride (0.5 mg/kg; AnaSed; Lloyd, Shenandoah IA) administered IV. The muscle
biopsy was performed in accordance to previously described procedures (115) where a
Bergstrom needle was used to aseptically collect muscle (~500 mg) from the gluteus
medius muscle. Following the biopsy, horses were given 2 g of the non-steroidal antiinflammatory phenylbutazone paste (ButaPaste; Butler Animal Health Supply, Dublin
OH), with additional doses given 24 and 48-hours later. After biopsy, horses were
returned to their stalls to be monitored. There were no incidences of biopsy site
infections, with the exception of minor swelling, in any horses in this study.
3.2.4 Plasma analysis.

The blood samples were transferred into evacuated glass tubes (Vacutainer;
Becton-Dickinson, Franklin Lakes NJ) coated with sodium heparin and refrigerated (4°C)
immediately until centrifuged at 1,000 x g at 4°C and plasma was aliquoted and stored at
-20°C. The two plasma samples taken before and after feeding were analyzed using an
automated analyzer (YSI 2300 STAT PlusTM Glucose and Lactate Analyzer, YSI Inc.,
Life Sciences, Yellow Springs, OH) to measure plasma glucose concentrations
enzymatically and a commercially available kit (Coat-A-Count RIA® kit Siemens,
Healthcare Diagnostics Inc., Deerfield, IL) to measure plasma insulin concentration. The
kit used has been previously validated for use in horses (208, 209). Additionally, plasma
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free amino acid concentrations were measured for these samples by HPLC analysis of
phenyisothiocyanate derivatives, as described previously (115).
Plasma samples collected during the isotope infusion procedures were analyzed
by an external laboratory (Metabolic Solutions, Nashua, NH) for the isotopic enrichment
of a t-butyldimethylsilyl derivative of phenylalanine (m+1) using GC-MS as previously
described (201, 210).
3.2.5 Breath sample analysis.
On the day of isotope infusion, the ratio 13CO2:12CO2 in exhaled breath samples
was determined using an isotope selective non-dispersive infrared absorption (NDIR)
analyzer (IRIS-2; Wagner Analysen Technik Vertriebs, Bremen, Germany).
3.2.6 Western immunoblot analysis.

Muscle homogenates were prepared according to previously described
procedures (116, 202). Briefly, following the muscle biopsy collection, a portion of
muscle (~100 mg) was homogenized in a lysis buffer. Homogenates were centrifuged at
10,000 x g for 10 min at 4°C and the supernatant was removed and frozen at -80°C until
the time of analysis. Protein content of the supernatant was determined using a Bradford
assay (Bradford Reagent, Sigma-Aldrich, St. Louis MO) and all samples were diluted in a
Laemmli to a 2 μg/μL concentration to be loaded into polyacrylamide gels. The proteins
were separated via electrophoresis, transferred to polyvinylidene diflouride membranes
and incubated for 1 hr in a 5% fat free milk solution with the exception of myostatin,
which was incubated in a 5% BSA solution. Next, membranes were incubated with the
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following primary antibodies: Akt (total and phosphorylated Ser473; 1:2000 dilutions for
each; Cell Signaling Technology, Beverly MA), rpS6 (total and phosphorylated Ser235/236
and Ser240/244; 1:10000 and 1:2000 of each antibody dilutions, respectively; Cell
Signaling Technology, Beverly MA), 4E-BP1 (total and phosphorylated; 1:1000 dilutions
of each; Cell Signaling Technology, Beverly MA), AMPKα (total and phosphorylated
Thr172; 1:1000 dilutions of each; Cell Signaling Technology, Beverly MA), FoxO1 (total
and phosphorylated Ser 256; 1:4000 and 1:5000 dilutions, respectively; Santa Cruz
Biotechnology, Dallas TX), NF-κB p65 (total and phosphorylated Ser536; 1:4000 and
1:1000 dilutions, respectively; Cell Signaling Technology, Beverly MA), MuRF1 (total;
1:5000 dilution; ECM Biosciences, Versailles KY), atrogin-1 (total; 1:1000 dilution;
ECM Biosciences Versailles, KY), myostatin (total;1:10,000 dilution; abcam, Cambridge
MA) and α-tubulin (total; 1:1000; Cell Signaling Technology, Beverly MA). Membranes
were then washed and incubated with a goat anti-rabbit secondary antibody conjugated
with horseradish peroxidase (BioRad, Hercules CA) for 1 hr at 20°C. Following washing,
membranes were developed with a chemiluminescent kit (Abersham ECL Plus Western
Blotting Detection System; GE Healthcare, Piscataway NJ) and developed using a film
processor (Kodak X-OMAT film processor, Kodak Health Imaging Division, Rochester,
NY). After developing, membranes were striped and re-probed with a second antibody in
order to account for the total amount of the protein of interest. In the case of
phosphorylated proteins, the antibody recognized the total form of the protein. α-tubulin,
which has previously been used to standardize protein abundance in equine skeletal
muscle (211), was used to standardize the abundance of MuRF1, atrogin-1 and myostatin,
because only the total abundance of protein was measured. Band densities were measured
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using a densitometric computer software (ImageJ, National Institutes of Mental Health,
Bethesda MD). The abundance of phosphorylated forms of Akt, S6K1, rps6, 4E-BP1,
AMPK, NF-κB and FoxO1 was corrected for the density of the total protein band and the
value for the control treatment was set at 1.0 arbitrary units. The abundance of MURF1,
atrogin-1 and myostatin were determined and compared to abundance of α-tubulin in
order to correct for total protein. All gels were run in duplicate.
3.2.7 Calculations.

3.2.7.1 Plasma phenylalanine enrichment
Plasma enrichment of [1-13C] phenylalanine, in molecules percent excess, was
calculated using a previously described formula (212).
3.2.7.2 Breath CO2 enrichment
For the breath samples collected during the [13C] sodium bicarbonate infusion,
total CO2 production was calculated based on breath CO2 enrichment using a previously
published formula (213). For all breath samples, the δ enrichment values obtained from
the nondispersive infrared absorption analyzer was converted to atoms percent excess
using a previously described formula (213).
3.2.7.3 Primed, constant infusion, whole-body phenylalanine kinetics

During phenylalanine enrichment, a plateau, defined as at least 4 values having a slope
not significantly different from 0 (P > 0.05) was determined using linear regression
analysis (GraphPad Prism 4 Software). The average plasma enrichment at isotopic steady
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state (plateau) was used to calculate whole-body phenylalanine kinetics. The plateau
enrichment values were then used to calculate the whole-body phenylalanine flux using
previously described formulas in the horse (188). Briefly, flux is equal to the amount of
phenylalanine entering the plasma pool through dietary intake (I), de novo synthesis (N)
and protein breakdown (B) or leaving the pool through protein synthesis (Z), oxidation
(E) or conversion to other metabolites (M):
Q= I + N + B = Z + E + M.
Intake was determined by multiplying dietary phenylalanine intake by 0.5 to account for
prececal phenylalanine digestibility (214) and the dietary phenylalanine that is extracted
during first-pass splanchnic metabolism in other monogastric species (215, 216) . In the
horse, phenylalanine is an indispensible amino acid, so de novo synthesis does not occur;
therefore protein breakdown can be estimated by:
B= Q – I.
Phenylalanine oxidation was calculated using the equations previously described (191).
Non-oxidative phenylalanine metabolism can be calculated by taking the difference
between phenylalanine flux and oxidation and is used as an indication of whole-body
protein synthesis. The major non-CO2 product of phenylalanine metabolism is tyrosine;
however, in the current study, the only source of dietary tyrosine was the pelleted
complete feed, which all of the horses received at the same intake level corrected for
body weight. Therefore, any reduction in whole-body phenylalanine oxidation would
suggest an increase in phenylalanine use for whole-body protein synthesis.
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3.2.8 Statistical analysis.

All data were analyzed using the mixed procedure of SAS (version 9.3; SAS Institute;
Cary NC) and data were considered significant at P < 0.05. Statistical trends were
considered at 0.05 < P <0.10.
Analyses of pre-feeding and post-feeding plasma metabolite concentrations were
assessed using a repeated-measures analysis, with group, time, and the interaction
between group and time as the fixed effects and horse nested in group as the random
effects. The variance-covariance matrix was chosen for each repeated-measures analysis
based on the lowest value for Schwarz’s Bayesian Criterion. Phenylalanine kinetics
parameters and western immunoblot data were analyzed using a 1-way ANOVA with
PPID status (group) as the fixed effect and horse nested in group as the random effect.
All data are presented as least square means and pooled standard errors.

3.3 RESULTS

3.3.1 Plasma insulin, glucose, and amino acids.

Plasma insulin, glucose, and amino acid concentrations were measured prior to
feeding and 90 minutes post-feeding. Plasma insulin (Table 3.1) and glucose (Table 3.1)
concentrations increased post-feeding (P< 0.01). Plasma glucose concentration was
higher post-feeding in the PPID horses compared to the CON horses (P= 0.02); however,
plasma insulin concentrations were not different between PPID and CON horses. There
was no effect of the interaction between time and PPID status on either plasma glucose or
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insulin concentrations (P> 0.05). Plasma amino acid concentrations were not affected by
time, PPID status or the interaction between time and PPID status (P > 0.05) (Table 3.1).
3.3.2 Western immunoblot data.
There was no effect of PPID status on the post-feeding activation of Akt at Ser473
(P= 0.93; Figure 3.1), rpS6 at Ser235/236 & 240/244 (P= 0.20; Figure 3.1), 4E-BP1 at Thr 37/46
(P= 0.36 ; Figure 3.1), NFκB p65 at Ser536 (P= 0.48; Figure 3.2), AMPKα at Thr172 (P=
0.54; Figure 3.3), myostatin (P= 0.27; Figure 3.3), FoxO1 (P= 0.85; Figure 3.4), MuRF1
(P= 0.67; Figure 3.4) or atrogin-1 (P= 0.53; Figure 3.4) (P > 0.05).
3.3.3 Whole-body phenylalanine kinetics.

There was no effect (P > 0.05) of PPID status on carbon dioxide production,
phenylalanine flux, phenylalanine intake, phenylalanine oxidation, phenylalanine release
from protein breakdown and non-oxidative phenylalanine disposal (Table 3.2).

3.4 DISCUSSION

Although a previous study examined some of the pathways associated with
muscle protein breakdown in horses with PPID compared to age-matched controls (16),
to the best of the authors’ knowledge, this was the first study to compare whole-body
protein synthesis and mTOR signaling between horses with PPID and age-matched, nonPPID horses. The current study showed that despite an increase in plasma insulin and
glucose concentrations post-feeding, there was no concurrent increase in the plasma
concentration of any of the indispensable amino acids 90 minutes following a meal.
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There were no differences in whole-body protein kinetics between the PPID and CON
horses, nor were differences seen in the abundance of any of the signaling factors
associated with protein synthesis and degradation that were studied. These findings
suggest that although PPID status does not affect whole-body protein metabolism or any
of the signaling pathways studied, advanced age may lead to a decreased ability to release
amino acids into the bloodstream post-feeding.
The only significant difference that was measured between the PPID and CON
groups in this study was that the PPID horses had a higher plasma glucose concentration
in response to feeding when compared to the CON horses, although pre-feeding values
were not different between the groups. Despite the differences in glucose concentration,
there were no differences in basal insulin concentrations or insulin concentrations postfeeding between the two groups of aged horses. This suggests that the PPID horses may
some dysregulation in insulin-mediated glucose uptake, since similar concentrations of
insulin were not able to stimulate glucose uptake as effectively in the PPID horses.
Previous studies have suggested increased insulin resistance in horses with PPID (18, 19)
and increased incidence of hyperinsulinemia (1); however, in all of these previous studies
the control group was much younger than the PPID horses due to the nature of PPID
affecting primarily aged horses. Differences in insulin sensitivity may help to explain
some of the associations between muscle atrophy and PPID. Understanding differences in
insulin sensitivity in horses with PPID compared to age-matched, non-PPID controls is
an area where additional research is warranted.
In the current study, plasma glucose and insulin concentrations at 90 minutes
post-feeding were increased compared to pre-feeding levels; however, feeding did not
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result in an increase in the plasma concentrations of any of the indispensable amino acids.
Previous research in horses has shown that plasma amino acid concentrations reach peak
concentrations around 90 minutes post-feeding (206); therefore the lack of postprandial
increase in the plasma amino acids at the t= 90 min sample in the current study was
unexpected. We have previously shown that feeding of a high protein meal (1.32g
protein/kg BW, divided between 2 meals which were separated by 30 minutes) resulted in
large increases in plasma glucose, insulin and amino acids concentrations and also
resulted in an increase in the activation of mTOR signaling factors in the skeletal muscle
of both mature (115, 116) and growing horses (116). The current study provided 0.86
g/kg BW protein in the meal, which is lower than the previous studies of mTOR signaling
in horses (115, 116); however, it is greater than in another previous study (0.55 g
protein/kg BW) (188) in mature horses where increases in plasma amino acid
concentrations were measured at 120 min post-feeding. Therefore, based on the literature,
it appears unlikely that the timing of the postprandial sample was not appropriate or that
the amount of protein fed was inadequate to measure the expected postprandial increase
in plasma amino acids concentrations.
It is possible that the lack of a postprandial increase in plasma amino acid
concentrations is a function of advanced age of the horses studied (~25 years) and
therefore affected both groups of horses in the current study. This hypothesis is consistent
of studies in old rats, which revealed that age alters splanchnic extraction of amino acids.
In aged rats, arterial plasma concentrations of AA were lower (20-30% less on average)
when compared to adult rats infused with amino acids (217). In horses, there is some
evidence to support that protein digestion may decrease with advanced age. In an early
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study, apparent crude protein digestion was reduced in aged horses (~25 yrs) when
compared with younger horses (~2 yrs) (195); however, in later studies of aged horses,
protein digestion was within the normal range of apparent protein digestion reported for
younger horses (196). Therefore, it is difficult to speculate whether the lack of
postprandial increase in plasma amino acid concentrations in the current study was due to
age-related alterations in dietary protein digestibility. The lack of increase in plasma
amino acid concentrations in these old horses is of interest because it could affect the
amount of anabolic stimuli that is present to stimulate the postprandial increase in muscle
protein accretion. The underlying cause of the lack of postprandial increase in plasma
amino acid concentrations in the aged horses in the current study warrants additional
research.
The muscle atrophy that has been described in horses with PPID may be due to
increased circulating inflammatory cytokines, because these have been shown to
stimulate protein breakdown (178). In the horse, inflammation has been shown to
increase with advancing age as part of a process known as inflamm-aging (218).
Interestingly, horses with PPID have been shown to have decreased (219) or similar (16)
expression of several inflammatory cytokines when compared to healthy aged-matched
controls. In the present study, inflammation was not measured directly, but no differences
were found in the relative abundance of phosphorylated NF-κB between the PPID and
CON. The phosphorylation and activation of NF-κB is stimulated by inflammatory
cytokines (179), thus it is unlikely that there was a difference in inflammatory signaling
in the skeletal muscle between the two groups of aged horses in the current study.
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In studies of aging in humans, some studies have found that the rates of whole
body muscle protein synthesis declined with age (187) , whereas other studies have found
that aging does not alter whole-body muscle protein synthesis (192). The authors
hypothesized that the lack of difference in protein anabolic responses may have been due
to similar muscle mass index and level of physical activity between the elderly and young
group (192). It has been demonstrated that up to 87% of the variance seen in whole-body
protein kinetics is due to differences in fat free mass (187). In the current study, fat free
mass was not measured directly, but both groups were of moderate body condition score
suggesting differences in fat-free mass between the two groups was minimal. This is
consistent with another study where no differences in whole-body protein metabolism
were measured between aged and mature horses of similar body condition scores (201).
In the current study, no significant differences were seen in any of the measures of
whole-body protein kinetics between the PPID and CON groups. These results differ
from what would be expected based on previous studies that have shown increased
muscle atrophy and increased expression of a factor associated with protein breakdown
pathway non-lysosomal calcium protease-dependent systems. The results from the
current study also differ from human studies where protein breakdown was increased in
patients with Cushing’s disease (200), further highlighting the differences between
human Cushing’s disease and PPID.
It is possible that no differences in whole-body protein kinetics were seen due to
the horses that were included in this study. All of the aged horses, regardless of PPID
status, included in the present study were relatively healthy, capable of being managed in
a group setting and did not exhibit visible signs of the extreme losses in fat free mass that
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can occur with age. It is possible that if more advanced cases of PPID had been included
in the current study, differences in whole-body protein metabolism may have been
measured between the PPID and CON groups. Whole-body protein kinetics only give
information about overall rates of protein synthesis and breakdown occurring in the body,
but do not provide specific information about the contribution of the individual tissues.
Therefore, although no differences in whole-body protein synthesis or breakdown were
seen in the present study, it is still possible that changes may exist on the muscle level
and thus the activation of the signaling pathways were studied in the skeletal muscle.
Protein synthesis is regulated through the mTOR pathway. Briefly, Akt is
activated by insulin and subsequently activates downstream factors of mTOR signaling,
rps6 and 4E-BP1, leading to protein synthesis. Glucocorticoids, which have been
hypothesized to be elevated over a 24-hr period in horses with PPID, have been shown to
decrease Akt phosphorylation in the horse (211). In the current study, no differences were
seen between the PPID and CON groups in the phosphorylation of any of the mTOR
signaling factors studied, suggesting that PPID status does not alter muscle protein
synthesis in response to feeding in the horse. Protein synthesis is stimulated by insulin
and negatively affected by glucocorticoid excess and this suggests that insulin sensitivity
and cumulative daily glucocorticoids may not be different between the two groups in the
current study, although this was not measured.
Myostatin acts as a negative regulator of skeletal muscle mass by inhibiting
activation of factors associated with mTOR signaling (155). Dexamethasone
administration, which has been shown to decrease skeletal muscle mass (152), leads to
increased myostatin expression in rats (153). In the current study, no differences were
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seen in muscle abundance of myostatin, which is consistent with previous studies of
PPID horses compared to age-matched controls (16). Another negative regulator of
protein synthesis is AMPK, a sensor of cellular energy, that is activated by rising AMP
levels as a result of energy starvation and results in mTOR inhibition (220). Due to the
differences in plasma glucose post feeding in the current study, it would be possible that
differences in AMPK phosphorylation could exist between the two groups of horses.
However, no differences were seen in phosphorylation of AMPK between the PPID and
CON groups, indicating no differences in cellular energy status exist between the two
groups of aged horses.
In addition to activating protein synthesis, Akt phosphorylation also has the
ability to affect protein breakdown through phosphorylation and subsequent inactivation
of FoxO (203), leading to an increase in protein breakdown through the ubiquitinproteosomal pathway. FoxO phosphorylation has been show to increase the expression of
MuRF1 and atrogin-1, two genes highly associated with muscle atrophy (166). Due to the
muscle atrophy previously associated with PPID (16), it would be expected to see an
increase in factors associated with ubiquitin-proteosomal protein breakdown pathway in
the PPID versus CON horses; however, this was not observed in the present study. There
were no differences seen between PPID and CON groups in the phosphorylation of
FoxO1, which is consistent with the lack of differences in the expression of MuRF1 and
atrogin-1. In a previous study of protein breakdown in horses with PPID versus age
matched controls, no significant differences were detected the expression of the major
proteolytic systems between the two groups with the exception of m-calpain, which had
greater expression in horses with PPID (16). Therefore, the results from the current study
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generally support the results from the previous study (16) that it is not the ubiquitinproteosomal pathway of protein breakdown that is affected by PPID status in aged horses.
Alternatively, it is possible that the muscle biopsy at 90 minutes post-feeding did
not effectively capture differences in the protein synthesis and breakdown pathways
between the two groups of aged horses. Further, the study only looked at the abundance
or phosphorylation of these factors post-feeding, so it is possible that response to other
anabolic stimuli, such as exercise, may in fact be different between the two groups. In the
current study, muscle biopsies were taken at 90 minutes post-feeding based on previous
studies of younger horses (115, 116). However, in the current study, no changes were
seen in plasma amino acid concentrations post-feeding, indicating 90 minutes may not
have been an appropriate time to take the muscle biopsy in aged horses. Since it is known
amino acids stimulated mTOR signaling (221), differences in the signaling pathways
between the two groups may have been missed. Further, the current study did not take a
pre-feeding muscle biopsy, so it is impossible to speculate if the meal was able to
stimulate a post-prandial increase in mTOR signaling, as seen in previous studies (115,
116). In human studies, aging has been shown to decrease the responsiveness of mTOR
signaling in response to anabolic stimuli, but differences are not always seen in a basal
state (222). The inability to stimulate mTOR or suppress protein breakdown in response
to feeding could be a potential mechanism to explain muscle loss as seen in aged horses
and in particular horses with PPID (17), although additional research would be needed to
specifically examine this hypothesis.
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3.5 CONCLUSION

The study highlights the importance of understanding amino acid requirements
and digestibility in all aged horses, because none of the horses in this study showed an
increase in plasma amino acid concentration in response to feeding. Although muscle
atrophy has been shown to be associated with PPID, no differences were seen in wholebody protein kinetics between the two groups of aged horses in the current study.
Additionally, although there is some evidence that insulin sensitivity may be lower in
horses with PPID, it does not seem to affect abundance or phosphorylation of the factors
associated with protein synthesis and breakdown that were studied in the muscle. None of
the factors associated with protein synthesis and breakdown in the muscle were different
between the two groups; supporting the idea that whole-body protein metabolism is not
affected by PPID status. The mechanisms underlying the loss of muscle mass in horses
with PPID requires additional investigation.

76

3.6 TABLES

Table 3.1. Glucose, insulin and amino acid concentrations in PPID and CON horses
before (0 min) and 90 min following a meal1
CON

PPID

p-values

0 min

90 min

0 min

90 min

Pooled SE

Group

Time

Group *Time

Glucose2

4.73

5.31a

5.35

6.28b*

0.27

0.02

0.01

NS

Insulin3

9.7

46.5*

20.2

61.4*

8.7

NS

0.001

NS

Histidine4

79

78

75

84

10

NS

NS

NS

Isoleucine

70

80

69

71

4

NS

NS

NS

Leucine

126

131

131

128

9

NS

NS

NS

Lysine

105

125

109

119

12

NS

NS

NS

Methionine

44

47

43

41

3

NS

NS

NS

Phenylalanine

68

73

59

61

6

NS

NS

NS

Threonine

124

129

149

152

12

NS

NS

NS

Tryptophan

13

13

12

13

1

NS

NS

NS

Valine

245

261

272

267

14

NS

NS

NS

1

Values are lease square means *Values that differed significantly (P < 0.05) from

baseline. a,b Values that were significantly different between the CON and PPID group at
the same time point.
2

Plasma glucose concentrations are reported as least squares means in mmol/L

3

Plasma insulin concentrations are reported as least squares means in µIU/mL.

4

Plasma amino acid concentrations are reported as least squares means in µmol/L.
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Table 3.2: Whole-body phenylalanine kinetics in PPID and CON horses1
CON

PPID

Pooled SE

P

Phenylalanine flux, μmol·kg-1·h-1

38

39

1

NS3

Carbon dioxide production, μmol·kg-1·h-1

14

15

1

NS

Phenylalanine from dietary intake3, μmol·kg-1·h-1

7

7

0

NS

Phenylalanine from protein breakdown2

30

31

1

NS

Phenylalanine oxidation3, μmol·kg-1·h-1

9

8

1

NS

Non-oxidative phenylalanine disposal,

29

31

1

NS

Phenylalanine entering the free phenylalanine pool

μmol·kg ·h
-1

-1

Phenylalanine leaving the free phenylalanine pool

μmol·kg ·h
-1

1

-1

Values are least square means. Labeled means in a row without a common letter differ,

P < 0.05. *Differs from the rate of non-oxidative phenylalanine disposal for that
treatment, P < 0.05.
2

The following stochastic model of phenylalanine kinetics was used: flux = rate of

phenylalanine entry = rate of phenylalanine leaving; rate of phenylalanine entry =
phenylalanine intake + phenylalanine release from protein breakdown; rate of
phenylalanine leaving = phenylalanine oxidation + non-oxidative phenylalanine disposal
3

NS, not significant, P > 0.05.
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3.7 FIGURES

Figure 3.1. Postprandial gluteal muscle phosphorylation of factors involved in the
upregulation of protein synthesis, Akt at Ser473, rpS6 at Ser235/236 & 240/244, and 4EBP1 at Thr 37/46 in CON (white bars) and PPID (black bars) horses. The
phosphorylated forms of the translation initiation factors were corrected by the respective
total form abundance, with the value for CON horses set to 1.0 AU. Values are least
square means ± pooled SE, n=6 per group. Representative images of the immunoblots are
shown above.
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Figure 3.2. Postprandial gluteal muscle phosphorylation of NFκB p65 at Ser536, an
indicator of inflammatory status, in CON (white bars) and PPID (black bars)
horses. The phosphorylated form of NFκB was corrected by the respective total form
abundance, with the value for CON horses set to 1.0 AU. Values are least square means ±
pooled SE, n=6 per group. Representative images of the immunoblots are shown above.
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Figure 3.3. Postprandial gluteal muscle phosphorylation of AMPKα at Thr172 and
relative abundance of myostatin, negative regulators of protein synthesis, in CON
(white bars) and PPID (black bars) horses. The phosphorylated form of αAMPK was
corrected by the respective total form abundance, and myostatin abundances were
normalized to α-tubulin, with the value for CON horses set to 1.0 AU. Values are least
square means ± pooled SE, n=6 per group. Representative images of the immunoblots are
shown above.
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Figure 3.4. Postprandial gluteal muscle phosphorylation of FoxO1 and relative
abundances of atrogin-1 and MuRF1 in CON (white bars) and PPID (black bars)
horses. The phosphorylated form of FoxO1 was corrected by the respective total form
abundance and atrogin-1 and MuRF1 abundances were normalized to total α-tubulin,
with the value for CON horses set to 1.0 AU. Values are least square means ± pooled SE,
n=6 per group. Representative images of the immunoblots are shown above.
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Chapter IV
Pituitary pars intermedia dysfunction does not affect insulin sensitivity in aged horses.

4.1 INTRODUCTION
Pituitary pars intermedia dysfunction (PPID), also known as equine Cushing’s
disease, is believed to affect 15-30% of aged horses (1, 2). The disease is caused by a
hypertrophy, hyperplasia, or adenoma formation on the pars intermedia of the pituitary
gland and typically occurs in horses older than 15 years of age (5). Clinical signs of PPID
include hypertrichosis (198), muscle atrophy (17), laminitis (41) , increased secondary
infections (36) and decreased insulin sensitivity (19).
Insulin resistance is defined as a condition in which normal concentrations of
insulin produce a subnormal physiologic response (66). Currently, two studies have
investigated the effects of PPID on insulin sensitivity in the horse; however, in both
studies it is likely that the PPID horses were much older than the control horses, due to
the nature of PPID affecting primarily aged horses (5). Garcia and Beech (18) determined
that horses with PPID (> 12 yrs old) did not respond to intravenous glucose
administration with an increase in insulin similarly to control horses (3 to 13 years old)
on the same diet. Another study used a euglycemic hyperinsulinemic clamp (EHC) and
found that horses with PPID (~21 yrs) had decreased insulin sensitivity compared with
healthy controls (~10 yrs) (19) . Insulin sensitivity has been shown to decrease with age
(88); therefore, it is likely age was a confounding factor in both of these studies and it is
still unknown whether insulin sensitivity is different between PPID and non-PPID aged
horses.
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Additionally, PPID has been associated with muscle atrophy (17). Muscle atrophy
occurs when the rate of protein degradation exceeds the rate of protein synthesis. The
signaling pathways associated with both protein accretion and breakdown are affected by
insulin (171, 223); therefore, insulin resistance could be a potential mechanism to explain
the muscle atrophy that occurs in the horse. It has been demonstrated that insulin
increases the phosphorylation of factors in the mechanistic target of rapamycin (mTOR)
signaling pathway, which is responsible for muscle protein synthesis (106), specifically
factors protein kinase B (Akt), eukaryotic initiation factor 4E-binding protein 1 (4EBP1), and riboprotein S6 (rpS6) are phosphorylated, ultimately leading to an increase in
protein synthesis. A previous study determined that there was an increase in the
activation of mTOR signaling factors of the skeletal muscle of mature (~14 year old)
horses in response to hyperinsulinemia (Urschel et al., unpublished); however, there has
only been limited research regarding muscle protein degradation in the horse (16).
Increased circulating inflammatory cytokines have been shown to induce loss of skeletal
muscle proteins through the activation of NFκB (179); however, inflammatory cytokines
in horses with PPID have been shown to have similar (16) or decreased (219) expression
when compared to age-matched controls. Akt activation also plays a role in protein
degradation as it has been shown to phosphorylate and inactivate nuclear transcription
factors Forkhead box O (FoxO) (203). When FoxO is activated, it increases the
expression of E3 ubiquitin ligases, atrogin-1 and muscle RING finger 1 (MuRF1), key
genes expressed during protein degradation (203). Muscle atrophy in the horse may also
be influenced by decreased protein synthesis due to AMP-activated protein kinase
(AMPK) (204) and myostatin (155) , both negative regulators of protein synthesis.
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The objective of this study was to compare insulin sensitivity in horses with PPID
compared to age-matched, non-PPID controls using a dynamic test and proxies to
measure insulin sensitivity. Further, the study aimed to characterize differences in the
activation of signaling pathways associated with muscle protein synthesis and breakdown
in response to insulin administration between the PPID and age-matched, non-PPID
control horses.

4.2 MATERIALS AND METHODS

The University of Kentucky Institutional Animal Care and Use Committee approved all
procedures in this study (2009-0562). Horses were obtained from an already established
herd of aged horses housed at the Department of Veterinary Science’s Maine Chance
Farm at the University of Kentucky.
4.2.1 Animals, housing and diets.

Twelve horses, older than 20 years of age, were classified as either PPID (n=6; 25.0±2.5
yrs; mean±SD) or age-matched, non-PPID control (CON) (n=6; 25.7±2.0 yrs). The
selected horses consisted of 10 Thoroughbreds (PPID: n=5; CON: n=5), one mixed breed
horse (CON: n=1) and one Quarter horse (PPID: n=1). Both the PPID and CON group
were comprised of 4 mares and 2 geldings of moderate body condition scores (PPID:
5.5±0.5; CON: 5.0±0.7; [scale 1-9] (205)). Horses classified as PPID exhibited a variety
of the classic physical signs associated with the disease including hirsutism,
hyperhydrosis, muscle atrophy, a history of laminitis, and hair coat abnormalities (8).
PPID classification was confirmed based on a resting ACTH greater than 50 pg/mL and
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serum cortisol greater than 1 μg/dL 19-20 hours following dexamethasone administration.
Blood for the plasma ACTH hormone assay was collected in April using EDTA tubes
(Vacutainer; Becton-Dickinson, Franklin Lakes, NJ) and sent to an external laboratory
for analysis (Animal Health Diagnostic Center; Cornell University, Ithaca, NY) that used
a chemiluminescent immunoassay to measure plasma ACTH. Plasma ACTH
concentrations were well above the 50 pg/mL cutoff for PPID horses (98.4±73.7 pg/mL)
and much lower in the CON horses (23.3±8.2 pg/mL). Dexamethasone suppression tests
were performed in May according the previously described procedures (39). Blood
samples were collected into glass evacuated tubes containing no additive (Vacutainer;
Becton-Dickinson, Franklin Lakes, NJ) before and 19-20 hours following an
intramuscular injection of dexamethasone at a dose of 0.04 mg/kg (DexaJect; Butler
Schein Animal Health, Dublin OH). Serum cortisol concentrations were determined by
an external laboratory (Animal Health Diagnostic Center; Cornell University, Ithaca,
NY), which used a chemiluminescent immunoassay to measure cortisol concentrations.
Cortisol was suppressed in the CON horses (0.46±0.32 µg/dL), but it did not suppress in
the PPID horses (2.27±0.92 µg/dL) consistent with a diagnosis of PPID. Horses were
returned to the Department of Veterinary Science’s herd of horses at the end of the study
and therefore it was not possible to perform a post-mortem examination for a more
definitive diagnosis of pituitary pars intermedia abnormalities.
All horses were housed in one paddock with free access to mixed grass hay (mean
± SD, as fed; 10.1± 0.1% crude protein, 33.0± 0.6% acid detergent fiber, 50.9± 0.6%
neutral detergent fiber, 2.7± 0.4% fat, and 6.5± 0.4% ash), water, and salt blocks. Horses
were fed a commercial concentrate (mean ± SD, as fed; 14.1± 0.1% crude protein, 22.5±
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0.7% acid detergent fiber, 37.2± 1.3% neutral detergent fiber, 6.2± 0.2% fat, and 7.4±
0.2% ash) (Purina® Equine Senior® Horse Feed, Purina Mills LLC, Gray Summit, MO)
individually in stalls twice daily (12g/kg BW/day), divided equally between meals at
0700 and 1500. Feed and hay samples were collected throughout the study by random
sampling and analyzed by Dairy One Forage Laboratory (Ithaca, NY). Horses were
adapted to the diets and housing for a minimum of 2 weeks prior to the euglycemic
hyperinsulinemic clamp (EHC) procedures
4.2.2 Experimental design and procedures.

4.2.2.1 Determination of basal values.

Prior to the day of the EHC procedures, horses were kept in stalls with free access to hay
and water. Twenty-four hours prior to the end of the EHC procedure, a 10 mL blood
sample was collected, via jugular vein venipuncture, to measure basal values for the
plasma concentrations of glucose, insulin and amino acids. Immediately after the blood
sample, horses were lightly sedated with xylazine hydrochloride (0.5 mg/kg BW)
administered IV (AnaSed; Lloyd, Shenandoah, IA). Then, a muscle biopsy was
performed in accordance with previously described procedures (202) where a muscle
tissue sample (~500 mg) was collected from the gluteus medial muscle using a Bergstrom
needle. Following the biopsy, horses were given 2 g of a non-steroidal anti-inflammatory
phenylbutazone (ButaPaste; Butler Animal Health Supply, Dublin, OH) and a meal was
fed. Horses were kept in stalls overnight (~18 hours) with free access to hay and water.
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4.2.2.2 The EHC procedure

The following day, catheters (14 gauge X 14.0 cm, Abbocath; Abbott
Laboratories, North Chicago, IL) were inserted into each jugular vein after the overlying
skin had been desensitized with 2% lidocaine (Lidocaine Injectable; Sparhawk
Laboratories, Inc., Lenexa, KS). One catheter was used for infusion of a 50% dextrose
solution (Bimeda Inc., Le Sueur MN) and insulin (Humulin N; Eli Lilly and Company,
Indianapolis, IN) while the second catheter was used for obtaining blood samples.
Immediately (-25 to -5 min) prior to the EHC procedures, four blood samples
were taken at 5-minute increments and analyzed for glucose concentration using a hand
held glucometer (Accu-Chek Aviva Plus; Roche Diagnostics, Indianapolis, IN). These
values were then averaged in order to determine resting glucose concentration. Horses
were outfitted with a surcingle and two infusion pumps. The insulin solution was
prepared by diluting recombinant human insulin into a 0.9% sterile saline solution for a
final concentration of 360 mU/mL. A priming dose of 0.4mU/kg BW insulin was given at
t=0 and then insulin infusion began at a rate of 1.2 mU/kg BW/minute as recommended
by previous research (224, 225), using a cordless intravenous pump (J-1097 VetPro
Infusion Pump, Jorgensen Laboratories Inc., Loveland, CO). Insulin infusion at this rate
has also been shown to activate factors in the mTOR pathway in the gluteus medius
muscle of mature horses (Urschel et al., unpublished). The EHC procedure was
performed as previously described (104), where insulin was infused at a constant rate and
the glucose rate was adjusted to maintain euglycemia. Once the procedure began, small
blood samples were taken every 5 minutes and glucose concentrations were measured
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with the hand held glucometer. When the blood glucose concentration fell below 10% of
the average baseline values, the infusion of the 50% dextrose solution was initiated using
a second peristaltic pump. Dextrose infusion was then adjusted throughout the procedure
in order to keep glucose values within 10% of baseline. In addition to the small blood
samples, 10 mL blood samples were taken every 15 minutes over the 120-minute
procedure for the determination of plasma glucose, insulin and amino acid concentration.
The blood samples were transferred into evacuated glass tubes (Vacutainer; BectonDickinson, Franklin Lakes NJ) coated with sodium heprin and refrigerated (4°C)
immediately until centrifuged at 1,500 x g at 4°C. Plasma was aliquoted and stored at 20°C until the time of analysis.
Following the EHC procedure, a second muscle biopsy was taken from the
opposing gluteus medius muscle using the same techniques as basal muscle biopsy. For
this biopsy, insulin and glucose infusion continued until the biopsy sample was collected
and thus this biopsy will be referred to as the insulin stimulated state biopsy (INS).
Similarly to the basal biopsy, horses were given 2 g of the non-steroidal antiinflammatory phenylbutazone (ButaPaste; Butler Animal Health Supply, Dublin, OH)
immediately following the muscle biopsy and then 24 and 48-hours following the
procedure. After the INS biopsy, insulin and dextrose infusion was stopped and horses
were returned to their stalls to be monitored. There were no evidence of any incidences of
hypoglycemia following the second biopsy or any signs of biopsy site infections, with the
exception of minor swelling, in any horses in this study.
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4.2.3 Plasma analysis.
An automated analyzer (YSI 2300 STAT PlusTM Glucose and Lactate Analyzer,
YSI Inc., Life Sciences, Yellow Springs, OH) was used to measure plasma glucose
concentrations enzymatically. A commercially available kit (Coat-A-Count RIA® kit
Siemens, Healthcare Diagnostics Inc., Deerfield, IL) was used to analyze plasma insulin
concentrations. The kit used has been previously validated for use in horses (208, 209).
Plasma free amino acid concentrations were measured by use of HPLC analysis of
phenylisothiocyanate derivatives, as described elsewhere (202).
4.2.4 Western immunoblot analysis.

Muscle homogenates were prepared as previously described (202). Briefly,
following the muscle biopsy collection, a portion of muscle (~100 mg) was homogenized
in a lysis buffer and centrifuged at 10,000 x g for 10 min at 4°C. Then the supernatant
was removed and frozen at -80ºC until the time of analysis. Supernatant protein content
was determined using a Bradford assay (Bradford Reagent, Sigma-Aldrich, St. Louis
MO). All samples were diluted in a Laemmli to a 2 μg/μL concentration prior to being
loaded into polyacrylamide gels. The proteins were separated via electrophoresis and then
transferred to polyvinylidene diflouride membranes, as previously described (148). All
proteins were incubated for 1 hr in a 5% fat free milk solution with the exception of
myostatin which was incubated in a 5% BSA solution. Then, membranes were incubated
with the following primary antibodies: Akt (total and phosphorylated Ser473; 1:2000
dilutions for each; Cell Signaling Technology, Beverly MA), rpS6 (total and
phosphorylated Ser235/236 and Ser240/244; 1:10000 and 1:2000 of each antibody dilutions,
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respectively; Cell Signaling Technology, Beverly MA), 4E-BP1 (total and
phosphorylated; 1:1000 dilutions of each; Cell Signaling Technology, Beverly MA),
AMPKα (total and phosphorylated Thr172; 1:1000 dilutions of each; Cell Signaling
Technology, Beverly MA), FoxO1(FKHR) (total and phosphorylated Ser 256; 1:4000 and
1:5000 dilutions, respectively; Santa Cruz Biotechnology, Dallas TX), NF-κB p65 (total
and phosphorylated Ser536; 1:4000 and 1:1000 dilutions, respectively; Cell Signaling
Technology, Beverly MA), MuRF1 (total; 1:5000 dilution; ECM Biosciences, Versailles
KY), atrogin-1 (total; 1:1000 dilution; ECM Biosciences Versailles, KY), myostatin
(total;1:10,000 dilution; abcam, Cambridge MA) and α-tubulin (total; 1:1000; Cell
Signaling Technology, Beverly MA). Membranes were then washed and incubated with a
goat anti-rabbit secondary antibody conjugated with horseradish peroxidase (1:10000
dilution; BioRad, Hercules CA) for 1 hr at 20°C. Following a final wash, membranes
were developed with a chemiluminescent kit (Abersham ECL Plus Western Blotting
Detection System; GE Healthcare, Piscataway NJ) and viewed using a film processor
(Kodak X-OMAT film processor, Kodak Health Imaging Division, Rochester, NY). After
developing, the membranes were striped and re-probed in order to measure the total
amount of the protein of interest or α-tubulin in the cases of MuRF1, atrogin-1 and
myostatin, where only total abundance of protein was measured. α-tubulin has been
previously used in other studies of equine skeletal muscle to standardize protein
abundance in Western blot analysis (211). Band densities were determined using a
densitometric computer software (ImageJ, National Institutes of Mental Health, Bethesda
MD). The abundance of phosphorylated forms of Akt, S6K1, rps6, 4E-BP1, AMPK, NFκB and FoxO1 was corrected for the density of the total protein band and the value for
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the control treatment was set at 1.0 arbitrary units. The abundance of MURF1, atrogin-1
and myostatin were determined and compared to abundance of α-tubulin in order to
correct for total protein. All gels were run in duplicate.
4.2.5 Calculations.
Glucose infusion rate, in μmol/kg/min, was plotted against time so area under the
curve (AUC) could be calculated using the trapezoidal rule (GraphPad Prism 4;
GraphPad, La Jolla CA). Tissue sensitivity to exogenous insulin (M/I30) was calculated
by dividing the rate of glucose infusion during the last 30 minutes (M) by the mean
plasma insulin (I) during the last 30 minutes of the EHC procedure. Additionally, insulin
sensitivity was assessed by the calculation of two proxies of insulin sensitivity that used
baseline glucose and insulin concentrations: the reciprocal of the square root of insulin
(RISQI) and the modified insulin-to-glucose ratio (MIRG), as previously described (96).
4.2.6 Statistical analysis.

Data was analyzed using a mixed procedure of SAS (version 9.3; SAS Institute
Inc, Cary NC) with significance reported at P <0.05. Statistical trends were considered at
0.05 < P <0.10.
Measures of glucose metabolism and insulin sensitivity were analyzed using a
one-way ANOVA with PPID status (group) as the fixed effect and horse nested in group
as the random effect. Plasma glucose, insulin and amino acid concentrations were
analyzed using repeated measures analysis with group, time and the interaction between
group and time as the fixed effects and horse nested in group as the random effects. A
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single baseline was determined by taking the average of the two baseline values for each
variable. For each repeated measures analysis, the appropriate variance-covariance matrix
was determined based on the lowest value for Schwarz Bayesian criterion. Basal and INS
plasma glucose, insulin and amino acid concentrations at the time of biopsy and western
blotting data were analyzed using a 2x2 factorial with group, insulin state (basal and INS)
and the interaction between group and time as the fixed effects and horse nested in group
as the random effects. All data are presented as least square means and pooled standard
errors.

4.3 RESULTS

4.3.1 Plasma metabolite concentrations at the time of biopsy.

Plasma glucose, insulin and indispensable amino acid concentrations were not
affected by PPID status (P > 0.05) or the interaction between PPID status and insulin
state (P > 0.05) (Table 4.1). Glucose concentrations were also not affected by insulin
state (P > 0.05) (Table 4.1). Plasma insulin concentrations were significantly greater in
the INS compared to the basal state (P < 0.05) (Table 4.1). Plasma isoleucine, leucine,
methionine, threonine and valine concentrations were lower in the INS than in the basal
state (P < 0.05), whereas the plasma concentrations of the other indispensible amino acids
were not different between the basal and INS state (P > 0.05) (Table 4.1).
4.3.2 Plasma metabolite concentrations during the EHC procedures.

During the EHC procedures, there was an effect of time (P< 0.001) and an
interaction between PPID status and time (P=0.04), but no effect of PPID status (P= 0.22)
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on plasma insulin concentrations (Figure 4.1). Plasma insulin concentrations were
increased ~9 fold at the time of the biopsy (t=120) when compared to baseline values.
Despite the increase in plasma insulin concentration over the course of the procedure,
plasma glucose concentrations were not different from baseline with the exception of a
few transient changes, particularly immediately after the initiation of insulin infusion
(Figure 4.1), consistent with the goal of the EHC procedure to maintain euglycemia. The
PPID horses had a trend to have higher plasma glucose concentrations (P=0.07) during
the EHC procedures compared to the CON group (Figure 4.1). There was a significant
effect of time (P< 0.001), but no interaction between PPID status and time (P= 0.89) for
plasma glucose concentrations during the EHC procedure (Figure 4.1).
For all of the plasma amino acids studied, no interaction between PPID status and
time (P> 0.05) was seen (Table 4.2). Plasma histidine and phenylalanine concentrations
were not affected by PPID status or time (P> 0.05). Plasma isoleucine (P=0.002), leucine
(P= 0.001), methionine (P= 0.01) and valine (P=0.04) concentrations decreased during
the EHC procedures, but there was no effect of PPID status (P> 0.05). Plasma threonine
(P= 0.01), lysine (P= 0.03) and tryptophan (P= 0.05) were all affected by PPID status,
with higher concentrations seen in the PPID horses. Plasma threonine concentration was
also affected by time (P= 0.05), but plasma lysine and tryptophan were not influenced by
time of insulin infusion (P> 0.05).
4.3.3 Measures of glucose infusion rate and insulin sensitivity.

During the last 30 minutes of the EHC procedure, glucose infusion reached a
plateau. At this time, the mean glucose infusion rate required to maintain euglycemia in
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horses with PPID was similar to that of the CON horses (P=0.67) (Table 4.3) indicating
no differences in insulin-dependent glucose disposal between the two groups. Further,
there was no effect of PPID status on AUC for total glucose infusion (P=0.96), the M/I30
ratio (P= 0.26), RISQI (P= 0.16) or MIRG (P= 0.61) indices (Table 4.3).
4.3.4 Abundance of factors associated with protein synthesis and breakdown.

Representative blots for the proteins of interest are shown (Figure 4.2-4.5). No
differences were found between the PPID and CON groups for any of the factors studied,
nor were there any significant interactions between PPID status and insulin status (P>
0.05). Insulin infusion significantly affected the phosphorylation of Akt (P< 0.001), rps6
(P= 0.003) and 4E-BP1 (P= 0.003) in the gluteus medius muscle (Figure 4.2). The
phosphorylation of NF-κB (Figure 4.3), AMPK (Figure 4.4), FoxO1 (Figure 4.5), and the
abundance of myostatin (Figure 4.4), atrogin-1 (Figure 4.5), and MuRF1 (Figure 4.5)
were not affected by insulin infusion (P> 0.05).

4.4 DISCUSSION

Although insulin sensitivity in horses with PPID has been compared to younger
controls (18, 19), to the authors’ knowledge, this is the first time that horses with PPID
have been compared to age-matched, non-PPID controls using a dynamic test. The results
of this study demonstrated that insulin sensitivity was not different between horses with
PPID and CON horses using the EHC procedure and proxies, RISQI and MIRG, to
measure insulin sensitivity (226). Further, this study marks for the first time that the
abundance of many of these protein breakdown factors has been studied in equine
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skeletal muscle. Increases in factors associated with protein synthesis were seen in
response to insulin administration; however, no differences were seen between the PPID
and CON groups for any of the protein synthesis and breakdown factors studied.
Together these findings indicated that PPID status does not affect insulin sensitivity on a
whole-body level or the ability of insulin to affect insulin-mediated signaling pathways at
the muscle level.
The human form of Cushing’s disease is highly associated with insulin
resistance, primarily due to high levels of circulating cortisol (226). Although horses with
PPID generally have basal cortisol levels within the reference range (14, 15), it has been
hypothesized that the cortisol circadian rhythm in horses with PPID may be abolished
leading to increased cumulative cortisol over a 24-hour period (39), and ultimately
insulin resistance in PPID horses. With the exception of slightly elevated plasma glucose
concentrations during the EHC procedure, our study shows little evidence to support the
hypothesis that the horses with PPID were more insulin resistant than CON horses.
Initially, it was reported that measuring basal insulin had a high sensitivity in diagnosing
PPID in horses (15); however, it does not appear to be specific indicator of PPID (227) as
many non-PPID horses may also be hyperinsulinemic. A large epidemiological study
compared horses with PPID to aged controls and found that basal hyperinsulinemia
occurred in 32% and 3% of horses, respectively. However, aged horses with PPID (~24
years) were significantly older than the group of aged horses without PPID (~19 years)
(1). Age is a factor that continually presents a problem when investigating the
relationship between PPID and insulin sensitivity due to the nature of PPID affecting
horses of advanced age. The results of this study suggest that age rather than PPID status
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may be responsible for the decrease in insulin sensitivity that has previously been
reported.
It is likely that a decrease in insulin sensitivity occurs with advancing age. A
study found that older horses (~27 yrs) needed nearly 200% and 150% more insulin to
respond to an oral glucose tolerance test than young (~7 yrs) and middle-aged (~15 yrs)
mares, respectively (87). Further, a relationship has been found between age,
inflammatory cytokines, and insulin sensitivity where older horses have increased
inflammatory cytokine production and decreased insulin sensitivity (88). A weakness of
the present study was that a control group of younger horses was not included in order to
compare the insulin sensitivity of older horses with younger adult horses using the EHC.
However, when the results of the present study are compared to another study done by
our lab group using the same EHC procedure in younger adult horses (~8 yrs), the aged
horses, both PPID and CON, showed ~75% decrease in rate of glucose infusion
compared with the younger adult horses in the previous study (228). The RISQI and
MIRG values for the PPID and CON horses can also be compared to the established
references ranges defined by Treiber et al. (229) using a group of healthy, mature horses
(~9 – 18 years). Using the established quintiles (229), the CON horses fell into the 3rd
quintile and PPID horses fell into the 1st quintile, with both groups in the bottom 50% of
the established range for RISQI, a proxy measure for insulin sensitivity. Both groups fell
into the 5th quintile for the MIRG (229), indicating that while these horses were
somewhat insulin resistant, they were able to compensate for this resistance with the
increased β-cell release of insulin.
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Alternatively, it is possible that insulin resistance may only affect horses with
advanced PPID at a greater rate than aged-matched, non-PPID controls. Advanced PPID
has been defined as those with hirsutism plus 3 or more clinical signs (1). Using this
definition, only one PPID horse in the current group had clinical signs consistent with
advanced PPID. This horse also had a basal insulin value of 34.1 μIU/ml, the highest of
any horse included in this study and consistent with a diagnosis of hyperinsulinemia
(230). All of the PPID horses included in the present study were relatively healthy and
capable of being managed in a group setting due to the nature of maintaining an aged
research herd. It is possible that if a greater number of horses with advanced PPID horses
were included in the present study, differences may be have been detected between the
PPID and CON groups. A study found that serum insulin concentrations were higher in
PPID horses that did not survive the 1-2 year treatment period than in those horses that
survived the entire study period (61). This suggests that hyperinsulinemia and, thus
insulin resistance, may be associated with end stage cases of PPID.
Inflammation in the horse has been shown to increase with advancing age as part
of a process known as inflamm-aging (218), leading to decreased insulin sensitivity (88)
and increased protein breakdown (178). Interestingly, one study found that horses with
PPID have decreased expression of several inflammatory cytokines when compared to
healthy aged-matched controls that are similar to those of younger adult horses (219). In
the present study, inflammation was not measured directly, but phosphorylation of NFκB is indicative of inflammatory status (179), with greater phosphorylation of NF-κB
being suggestive of increased inflammatory signaling. No differences were found in the
relative abundance of phosphorylated NF-κB between the PPID and CON groups in the
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basal or insulin-stimulated state, thus it is unlikely that there was a difference in
inflammatory signaling in the skeletal muscle between the two groups of aged horses in
the current study.
Insulin has the potential to affect protein synthesis through the activation of the
mTOR signaling pathway, by phosphorylating Akt (119) . In the present study, no
differences were seen between PPID and CON groups in phosphorylation of factors
leading to protein synthesis, in either the basal of INS state. There were no differences
between the PPID and CON horses in the plasma concentrations of glucose, insulin, or
concentration of any of the amino acids at the time of either biopsy, which likely explains
why no differences were seen in the activation of any of the mTOR signaling factors
studied between these two groups of horses. However, the activation of both upstream
factors, Akt, and downstream factors, rps6 and 4E-BP1, in the mTOR signaling pathway
increased with the infusion of insulin by ~156%, 40% and 31%, respectively. The results
of this study were consistent with a previous study that found insulin infusion increased
the phosphorylation of factors associated with protein synthesis (Urschel et al.,
unpublished).
At the time of biopsy, the plasma concentration of many of the indispensable
amino acids were lower in the INS state than in the basal state, providing evidence that
these amino acids were removed from the plasma and used in protein synthesis. A
decrease in the concentration of the indispensible amino acids in the plasma is consistent
with other studies using the EHC procedure in horses (Urschel et al., unpublished),
humans (231) and pigs (232) . Although it is likely that the horses used in this study had
decreased insulin sensitivity due to their advanced age, it appears they still had the ability
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to respond to insulin with increased phosphorylation of factors associated with protein
synthesis. It is important to note that the signaling factors studied are simply indicators of
protein synthesis; however, studies in other species have shown that activation of mTOR
signaling factors also coincided with an increase in muscle protein fractional synthesis
rates (233). It is difficult to speculate if the aged horses had a decreased mTOR signaling
response to insulin compared to younger horses, since a younger control group was not
included in this study. However, in another study no differences were found in the
phosphorylation of Akt, rps6 and 4E-BP1 between mature and aged horses in a postabsorptive state (Wagner et al., in press), suggesting protein synthesis in the skeletal
muscle in the horse may not be greatly affected by age specifically, although in the
previous study differences between mature and aged horses were not determined in a
stimulated (ie. post-feeding) state and therefore additional research is still needed.
Myostatin acts as a negative regulator of skeletal muscle mass by inhibiting
activation of Akt, mTOR and p70 S6 kinase 1 (155). In human studies of insulin
resistance, plasma myostatin has been shown to be increased (234); however, no
differences were seen in muscle abundance of this protein in the current study, which is
consistent with previous studies of PPID horses compared to age matched controls (16).
These results are in agreement with our conclusion that there is not an apparent difference
in insulin sensitivity between PPID and CON horses. Another negative regulator of
protein synthesis is AMPK, which is a sensor of cellular energy that is activated by rising
AMP levels as a result of energy starvation and results in mTOR inhibition (220). AMPK
may also have an important function in muscle wasting as it has been shown to increase
the expression of MuRF1 and atrogin-1 (235). In the present study, no differences were
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seen in phosphorylation of AMPK between the PPID and CON groups, indicating no
differences in cellular energy status.
Insulin mediates protein breakdown through the phosphorylation of Akt which
has been demonstrated to phosphorylate and inactivate FoxO (203), leading to a decrease
in protein breakdown. Muscle atrophy occurs when the rate of protein breakdown
exceeds the rate of protein synthesis. Due to the muscle atrophy associated with PPID
(16), it would be expected to see an increase in factors associated with protein
breakdown in the PPID compared to age-matched, non-PPID control horses; however,
this was not observed in the present study. It has been proposed that major causes of
muscle atrophy include insulin resistance and inflammation (178); however, it appears
that there was no difference in insulin resistance and inflammation between horses with
PPID and CON horses in the present study.
In particular two genes, MuRF1 and atrogin-1 have been shown to have increased
expression in multiple models of skeletal muscle atrophy, such as including diabetes,
cancer, and adrenal failure (166). In the present study, no differences in MuRF1and
atrogin-1 expression or phosphorylation of FoxO were seen between the two groups of
aged horses, indicating no differences in skeletal muscle protein breakdown. Moreover,
insulin infusion did not reduce the abundance or activation of any of the studied factors
associated with protein breakdown. In a study using the EHC procedure in humans, a
biopsy at 30 minutes into the insulin infusion revealed marked increases in
phosphorylated FoxO expression (236), indicating that the 2 hour time period of insulin
infusion should have been long enough to cause an increase in FoxO phosphorylation in
the current study. It is possible that because FoxO regulation of MuRF1 and atrogin-1
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abundance occurs at the transcriptional level, that 2 hours may not have been sufficient to
measure changes in the abundance of MuRF1 and atrogin-1. However, the lack of an
effect of PPID or insulin status on MuRF1 and atrogin-1 is consistent with the lack of
change in FoxO phosphorylation under these same conditions. It is known that insulin
mediated signaling through the Akt pathway is non-linear (236), suggesting that even
though Akt signaling had a normal response to insulin in the current study, it is possible
that defects still exist insulin-dependent phosphorylation of factors downstream of Akt,
such as FoxO . Therefore, the lack of insulin-mediated suppression of protein breakdown
pathways provides some evidence that a portion of the muscle atrophy associated with
old horses may be due to a decreased ability to suppress protein breakdown in response to
anabolic stimulus. This is consistent with studies in rats and humans that have shown a
decreased stimulatory effect of food intake on protein synthesis and its inhibitory effect
on protein breakdown with old age (237, 238). The effect of aging on the balance
between protein synthesis and breakdown pathways in the skeletal muscle of the horse is
an area where additional research is warranted.
It is still possible that there were differences in whole-body protein metabolism
between the PPID and CON groups that were not captured by measuring the abundance
or activation of the selected factors in the skeletal muscle. The horses with PPID had
increased plasma concentrations of lysine, threonine and tryptophan when compared to
the CON horses during the EHC procedures, indicating that there may be some
differences in whole-body amino acid utilization between these two populations of aged
horses. Plasma indispensable amino acid concentrations represent a balance between the
processes that add and remove amino acids from the blood. Both groups had similar
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access to hay during the EHC procedure with minimal intake in both groups. Therefore,
the other main mechanism where additional amino acids could have been added to the
plasma would be through an increase in whole-body protein breakdown. Alternatively,
elevated plasma amino acid concentrations could also indicate a reduction in amino acid
use for protein synthesis in the PPID horses. A previous study in our laboratory utilized
isotope infusion techniques in order to measure whole-body protein synthesis in horses
with PPID compared to age-matched, non-PPID controls (Chapter III). The whole-body
protein kinetics data provides no evidence that there were any differences in whole-body
protein amino acid utilization between the PPID and age-matched, non-PPID control
horses and therefore the cause of the differences in amino acid concentrations between
the two groups of aged horses during the EHC procedures is an area that requires
additional research.
4.5 CONCLUSION

Although reduced insulin sensitivity is commonly associated with PPID, it had
never been evaluated using a dynamic test comparing horses with PPID and CON horses.
The results of this study indicate that reduced insulin sensitivity may occur as a normal
part of aging, but is not directly associated with PPID status. Further, PPID status does
not seem to alter the ability of insulin to affect insulin-mediated signaling pathways at the
muscle level. The decrease in insulin sensitivity as seen in aged horses compared to their
younger cohorts appears to be a multi-faceted condition with many other causes other
than just PPID. Since all aged horses, regardless of PPID status, have the potential to be
affected by reduced insulin sensitivity, it is important that all aged horses be monitored
for potential problems associated with insulin resistance.
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4.6 TABLES

Table 4.1. Plasma glucose, insulin and indispensable amino acid concentrations at
the time of biopsy collection in PPID and CON horses in the basal and insulin
stimulated state 1
CON

PPID

BASAL

INS

BASAL

INS

Pooled SE

Glucose2

4.37

4.64

4.90

5.37

0.36

Insulin3

10.4

109.0*

16.0

136.4*

13.9

Histidine4

45

41

48

43

5

Isoleucine

60

40*

63

46*

5

Leucine

101

65*

119

80*

12

Lysine

71

66

85

77

7

Methionine

33

22*

33

23*

4

Phenylalanine

59

50

47

45

6

Threonine

94

74*

110

91*

10

Tryptophan

43

39

58

52

6

Valine

190

138

231

166*

21

1

Values are least square means, n=6/group, as determined using a 2x2 factorial with

group, time (basal and EHC) and the interaction between group and time as the fixed
effects and horse nested in group as the random effects. No differences were seen
between group or an interaction between group and time. *Within a group, value differed
significantly (P < 0.05) from baseline.
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2

Plasma glucose concentrations are reported as least squares means in mmol/L

3

Plasma insulin concentrations are reported as least squares means in µIU/mL.

4

Plasma amino acid concentrations are reported as least squares means in µmol/L.
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Table 4.2: Plasma indispensable amino acid concentrations (mmol/L) in CON and
PPID horses in the basal and insulin stimulated state1
Group
CON

p-values
PPID

Pooled SE

Histidine
Baseline

42

56

5

30 min

41

46

5

120 min

40

43

5

Isoleucine
Baseline

53

65

4

30 min

52

59

4

120 min

40*

46*

4

Leucine
Baseline

86

122

11

30 min

88

104

11

120 min

65

80*

11

Lysine
Baseline

71a

107b

9

30 min

74

94

9

120 min

66

77

9

Methionine
Baseline

26

30

3

30 min

25

31

3
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group

time

group*time

NS2

NS

NS

NS

0.002

NS

NS

0.001

NS

0.03

NS

NS

NS

0.01

NS

Table 4.2 continued: Plasma indispensable amino acid concentrations (mmol/L) in
CON and PPID horses in the basal and insulin stimulated state
120 min

22

23*

3

Phenylalanine
Baseline

54

59

5

30 min

54

58

5

120 min

50

45

5

Threonine
Baseline

88a

113b

9

30 min

79

100

9

120 min

74

91*

9

Tryptophan
Baseline

39a

64b

5

30 min

41a

56b

5

120 min

39

52

5

Valine
Baseline

155

210

18

30 min

158

190

18

120 min

138

166*

18

1

NS

NS

NS

0.05

0.05

NS

0.01

NS

NS

NS

0.04

NS

Values are least square means (in mol/L), n = 6/treament, as determined using a

repeated measures analysis with compound symmetry used as the variance-covariance
matrix.

a,b

Values with different subscripts differ significantly at the same time point.

*Within a group, value differed significantly from baseline, P < 0.05.
2

NS, not significant, P > 0.05
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Table 4.3: Measures of glucose metabolism and insulin sensitivity for PPID (n=6)
and CON groups (n=6) during the euglycemic hyperinsulinemic clamp procedures1

Group
CON

PPID

Pooled SE

p-value

RISQI (mIU/L)-0.5

0.34

0.27

0.03

NS2

MIRG (mIUinsulin2/[10∙L∙mgglucose])

6.61

7.27

0.89

NS

Glucose AUC ( mmol/kg)3

1239

1230

147

NS

M30 (mmol/kg/min)4

13.0

11.7

2.04

NS

M/I30 (mmol/kg/min per mIU/mL)5

0.129

0.094

0.022

NS

1

All values are least square means, n=6/treatment. No differences were seen between the

two groups (P > 0.05).
2

NS= not significant, P > 0.05

1

Total glucose infusion during the clamp procedures.

2

Mean glucose infusion rate during the final 30 minutes of the clamp.

3

Tissue sensitivity to exogenous insulin.
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4.7 FIGURES

Figure 4.1. Plasma insulin concentrations (µIU/mL) in PPID (filled circle) and CON
(open circle) and plasma glucose concentrations (mmol/L) in PPID (filled square)
and CON (open square) during euglycemic hyperinsulinemic clamp procedures.
Values are least square means ± pooled SE, n=6/group, determined by repeated measures
analysis using the compound symmetry variance-covariance matrix for glucose and the
autoregression heterogeneous variance-covariance matrix for insulin. Overall, insulin
concentrations were effected by time (P< 0.001) and interaction between group and time
(P= 0.04); however, there was no effect of PPID status (P=0.22) on plasma insulin
concentrations during the EHC procedure. Plasma glucose concentration showed a trend
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(P=0.07) to be higher in the PPID horses than in the CON horses. There was an effect of
time (P< 0.001), but no interaction between treatment and time (P= 0.89).
*Significantly different from baseline, P < 0.05.

110

111

Figure 4.2. Gluteal muscle phosphorylation of factors involved in the upregulation
of protein synthesis, Akt at Ser473, rpS6 at Ser235/236 & 240/244, and 4E-BP1 at Thr 37/46
in CON and PPID horses during the basal (white bars) and insulin stimulated state
(black bars). The phosphorylated forms of the translation initiation factors were
corrected by the respective total form abundance, with the value for CON horses in the
basal state set to 1.0 AU. Values are least square means ± pooled SE, n=6 per group.
Representative images of the immunoblots are shown above. *Values with significantly
(P<0.05) different from baseline.
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Figure 4.3. Gluteal muscle phosphorylation of NF-κB p65 at Ser536 in CON and
PPID horses during the basal (white bars) and insulin stimulated state (black bars).
The phosphorylated form of NF-κB was corrected by the respective total form
abundance, with the value for CON horses in the basal state set to 1.0 AU. Values are
least square means ± pooled SE, n=6 per group. Representative images of the
immunoblots are shown above.
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Figure 4.4. Gluteal muscle phosphorylation of negative regulators of protein
synthesis, AMPKα at Thr172 and relative abundance of myostatin, in CON and PPID
horses during the basal and insulin stimulated state. The phosphorylation of αAMPK
was not affected by PPID status and did not differ between the basal (white) and insulin
stimulated state (black). There was no interaction between PPID and insulin status. The
phosphorylated form of αAMPK was corrected by the respective total form abundance,
with the value for CON horses in the basal state set to 1.0 AU. Values are least square
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means ± pooled SE, n=6 per group. Representative images of the immunoblots are shown
above.
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Figure 4.5. Gluteal muscle phosphorylation of FoxO1 and relative abundances of
atrogin-1 and MuRF1, factors associated with protein degradation, in CON and
PPID horses during the basal (white bars) and insulin stimulated state (black bars).
The phosphorylated form of FoxO1 was corrected by the respective total form abundance
and atrogin-1 and MuRF1 abundances were normalized to total α-tubulin, with the value
for CON horses in the basal state set to 1.0 AU. Values are least square means ± pooled
SE, n=6 per group. Representative images of the immunoblots are shown above.
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Chapter V

Summary, General Discussion and Future Directions

5.1 SUMMARY OF THE EFFECTS OF PPID ON THE AGED HORSE

The primary objective of this thesis was to determine the effects of PPID on
protein metabolism (Chapter III) and insulin sensitivity (Chapter IV) in aged horses, with
and without PPID. The first study in this thesis (Chapter III) examined the effect of PPID
on protein metabolism at the whole-body and skeletal muscle levels, by using isotope
infusion techniques and analyzing specific factors associated with muscle protein
synthesis and breakdown. The second study included in this thesis (Chapter IV)
determined the effect of PPID on insulin sensitivity using euglycemic-hyperinsulinemic
clamp techniques to measure insulin sensitivity at a whole-body level and further
characterized insulin-mediated signaling by looking at factors associated with protein
synthesis and breakdown. The results of these studies suggest:
1. PPID does not significantly alter protein metabolism in the horse at the wholebody or skeletal muscle levels.
2. Aging may lead to a decrease in insulin sensitivity in all aged horses, not only
those affected by PPID.
3. PPID status does not significantly alter insulin sensitivity; however, some
deregulations in glucose metabolism may exist in aged horses with PPID.
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4. Aging may produce an abnormal response to feeding where amino acids to not
reach the blood stream of the aged horse post-feeding to the same extent as in
younger horses.
5. Overall, the studies suggest that age rather than PPID status may be
responsible for the abnormalities in muscle mass and insulin sensitivity that
have previously been listed as characteristics of PPID.

5.2 GENERAL DISCUSSIONS AND FUTURE DIRECTIONS CONCERNING
RESEARCH OF PPID AND AGED HORSES.

Although it is estimated that PPID affects 15-30% of aged horses (1, 2) , few
studies have compared the clinical signs associated with PPID to age-matched controls.
For most of the clinical signs associated with PPID the association is purely anecdotal
based on observations from researchers and veterinarians; however, very few studies
have actually compared these clinical signs to healthy aged horses, in order to understand
the prevalence of these clinical signs in the normal aging horse population. Currently, the
NRC does not make specific nutritional recommendations for aging horses, due to the
lack of research in this field. However, it appears that physiologic differences, such as
insulin resistance, may exist between the mature and aged horses making more research
on aged horses needed. The research presented in this thesis did not look at the entire
aging horse population, but instead chose to look at horses with PPID, a subset of the
total population. Interestingly, the overall results from both studies showed very few
differences between the two groups of aged horses.
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When making comparisons to previous research in younger horses, it appears that
some of the abnormalities seen in both studies may be a function of age rather than PPID
status. Both studies presented in this thesis would have benefited from having a younger
control group. The original objective of this research was to see how whole-body protein
metabolism would differ between a population of horses that presumably had increased
insulin resistance and increased muscle atrophy compared to the normal aging
population. Initially, when making this comparison, it would seem that a younger control
group was not necessary to complete the described objective. However, the differences
between the two populations turned out to not be as distinct as previously suggested in
the literature.
Part of the discrepancy between the results of the studies presented in this thesis
and previous research is likely due to age and the progressive nature of PPID. As
previously mentioned, prior studies of insulin sensitivity in aged horses compared horses
with PPID to a younger population of horses (18, 19). This was likely due to the nature of
PPID affecting horses of advanced age, and lack of understanding of the decrease in
insulin sensitivity associated with age. Further, accurately diagnosing PPID, particularly
in the early stages, is difficult due to the low sensitivity of diagnostic tests. It is likely that
in previous studies, advanced cases of PPID were chosen, since those were the horses
visibly affected, making them easy to characterize as PPID.
In the current research, the opposite problem may have occurred. This is to say
that our study criteria likely selected for a healthier PPID horse. The horses included in
this study were initially selected from a herd of 60 aged research horses. All of the horses
in the herd were tested for plasma ACTH concentrations. Then, all horses with an ACTH
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concentration greater than 50 pg/mL were given a dexamethasone suppression test to see
if they would qualify for inclusion into the study. Using this method, some horses that did
not stand out from the herd as being PPID based on appearance, since they did not
present with substantial hirsutism, were included in the study. Further, PPID is a
progressive degenerative disease, and studies have shown that an increase in clinical
signs occurs with increasing age (1). PPID also affects horses differently and a variety of
clinical signs can be seen. To be included as part of the research herd at University of
Kentucky’s Department of Veterinary Sciences, aged horses must be healthy and capable
of being managed in a group setting. Due to these criteria, the PPID horses selected may
have been atypical. For example, it has been demonstrated that horses with PPID have an
increased predisposition for laminitis (41); however, if a horse in the research herd had
chronic bouts of laminitis, it would likely be culled from the herd. Laminitis has been
shown to be prevalent in horses with hyperinsulinemia or insulin resistance (22, 76);
therefore, our herd may have been unknowing selected toward the healthier PPID horses,
with clinical signs that do not require additional maintenance, and away from the
extremely insulin resistant horse.
Even if horses in the aged research herd were selected toward the healthier aged
horse, it still doesn’t explain some of the unexpected findings that occurred in both
groups of horses studied. Thus, additional research is needed in the aged population as a
whole to explain some of the derailments in insulin-mediated glucose uptake and
abnormal amino acid responses post-feeding. Both groups of aged horses had a glucose
infusion during the last 30 minutes of the EHC that was about 75% lower than horses (~8
years old) in another study by our laboratory group (228). This observation suggests, that
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age rather than PPID status may be responsible for the decreased insulin sensitivity that is
seen in aged horses. Further, both the PPID and age-matched, non-PPID horses had an
increase in glucose and insulin post-feeding as seen in previous studies. However, neither
group had an increase in plasma amino acid concentrations post-feeding which suggests a
potential decrease in amino acid digestibility or increased amino acid utilization by the
splanchnic tissues. Previous studies have demonstrated that apparent crude protein
digestion was reduced in aged horses (~25 yrs) when compared with younger horses (~2
yrs) (195); however, the low protein digestibility seen in the aged horses was not
observed in subsequent studies (196). However, the later studies did not include a
younger control group, so it is difficult to speculate if differences in protein digestibility
may have existed between the aged horses and younger controls. The current study
suggests that this research needs to be revisited, as neither of the groups of aged horses
included in this study showed the normal response to feeding of an increase in plasma
amino acid concentrations. Further investigation of protein digestibility and absorption in
the horse is warranted and may have important implications for the feeding of the senior
equine.
The studies included in this thesis leave many unanswered questions about PPID
and the effects it may have on the aged horse. The problem with studies of PPID is the
variety and severity of symptoms that may present in the horse. In future studies of PPID,
it seems a larger population of PPID horses may be needed in order to better characterize
a typical PPID horse. Further, it may be necessary to classify PPID horses as early stage
or advance stage PPID, based on their clinical signs, in order to better characterize PPID
horses. New research of PPID should focus on looking at improved diagnostic methods in
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order to better diagnose early stage cases of PPID, which is currently limited by the
available diagnostic methods.
Ultimately, the research presented in this thesis suggests that horses with PPID
and non-PPID aged horses may not have as many differences as initially believed. No
differences were seen between the two groups of horses in insulin sensitivity or wholebody protein metabolism. Further, no differences were seen between the PPID and agematched, non-PPID control groups in signaling factors associated with protein synthesis
and breakdown pathways, nor did PPID status affect the ability of insulin to stimulate
these pathways.
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